Developmental Malformations-Deafness-Dystonia Syndrome

Mendelian MONDO:0011823 Pathograph 16 Show in embeddings browser Dystonia-deafness syndrome Actinopathy

A dominant disorder of cytoplasmic beta-actin, caused in essentially every reported patient by the same variant: ACTB c.547C>T, p.Arg183Trp. Arginine 183 sits beside the nucleotide-binding pocket, and replacing it with tryptophan creates a stacking interaction with Tyr69 that traps the monomer in a closed conformation, perturbing nucleotide release and polymerization. Patient cells are morphologically abnormal and resist latrunculin A, so the defect shows up as altered depolymerization dynamics rather than as absent actin. What makes the entry interesting is that one constitutive molecular lesion produces three phenotypes that appear in sequence across a lifetime - craniofacial dysmorphism at birth, sensorineural deafness in infancy, generalized dystonia in adolescence or young adulthood. The published explanation is a temporal-vulnerability model: beta-actin is doing different jobs at different stages, and each phenotype appears when the job it is failing at becomes rate-limiting. The deafness arm has independent support - conditional Actb deletion in mouse hair cells spares stereocilia development and impairs stereocilia maintenance, which is the same developmental-versus-maintenance split the human timing implies. The dystonia arm has in vivo human imaging: reduced striatal D2-receptor binding and reduced striatal glucose uptake. This is deliberately NOT curated as a subtype of Baraitser-Winter cerebrofrontofacial syndrome, although ACTB causes that too and kb/disorders/Baraitser-Winter_Cerebrofrontofacial_Syndrome.yaml already carries a BRWS1 subtype for the gene. The variant here is recurrent and specific, the original report describes the phenotype as its own entity rather than as a mild Baraitser-Winter, and the later series describe it as distinct and overlapping rather than nested. MONDO gives it a separate term. If a reviewer disagrees, the remedy is a has_subtypes entry on that file, and the argument should be had on the evidence rather than on the shared gene. No pathophysiology node declares conforms_to. kb/modules/ was searched for an actin-cytoskeleton, stereocilia-maintenance or striatal-degeneration module. sensorineural_hair_cell_loss is the closest and was rejected: its chain runs through cochlear ionic homeostasis, oxidative stress and mechanotransduction failure, whereas the lesion here is structural maintenance of the stereociliary actin core with normal development. parkinsonism_dopaminergic_degeneration was also read and rejected: the imaging here shows striatal postsynaptic and metabolic deficit with only slight nigrostriatal transporter abnormality, which is not that module's nigral degeneration.

Ask OpenScientist

Ask a research question about Developmental Malformations-Deafness-Dystonia Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
11
Phenotypes
3
Gaps
16
Pathograph
1
Genes
5
Medical Actions
1
Models
1
Deep Research
👪

Inheritance

1
Autosomal Dominant HP:0000006
Heterozygous. Reported patients include monozygotic twins in the original family and subsequent apparently de novo cases.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:16685646 SUPPORT Human Clinical
"The disease phenotype includes developmental midline malformations, sensory hearing loss, and a delayed-onset generalized dystonia syndrome in monozygotic twins."
The original description. The dominant mode is in the paper's own title; this sentence carries the phenotype and the monozygotic-twin ascertainment.
?

Discussions and Knowledge Gaps

3
Is the sequential appearance of craniofacial, auditory and striatal phenotypes really explained by stage-specific beta-actin requirements, and does gamma-actin upregulation buffer it?
KNOWLEDGE GAP temporal_vulnerability_model_untested
Attached to
pathophysiology#Altered Actin Filament Depolymerization Dynamics pathophysiology#Stereocilia Maintenance Failure pathophysiology#Striatal Actin Turnover Failure pathophysiology#Neural Crest Migration Disturbance phenotypes#Absent septum pellucidum
All three branch edges in this pathograph rest on one hypothesis stated in one paper, and the entry marks them INDIRECT_UNKNOWN_INTERMEDIATES for that reason. The model is attractive and partly corroborated - the mouse stereocilia work independently shows a development-versus-maintenance split in the right direction - but nothing has tested it for p.Arg183Trp in any tissue. The proposed buffering by gamma-actin upregulation would explain why monozygotic twins and an unrelated case with the identical variant differ in whether they have midline malformations at all, and it has not been measured in patient tissue either. There is also a malformation the hypothesis does not reach at all. A third patient has an absent septum pellucidum on an otherwise normal brain MRI. The septum pellucidum is a midline forebrain derivative, not a neural crest derivative, so the craniofacial branch of this model cannot account for it and this entry leaves that phenotype without an upstream node. Since "developmental malformations" is the first word of the disease name, a mechanism that explains the face but not the midline CNS is an incomplete account rather than a nearly complete one.
Should this be a separate disease entry or a has_subtypes entry on Baraitser-Winter cerebrofrontofacial syndrome?
KNOWLEDGE GAP separate_entity_versus_bwcff_subtype
Attached to
disease#Developmental Malformations-Deafness-Dystonia Syndrome
ACTB causes both, kb/disorders/Baraitser-Winter_Cerebrofrontofacial_Syndrome.yaml already carries a BRWS1 subtype for the gene, and one reported patient here had mild dysmorphic features that would not look out of place there. The case for separation is that the variant is recurrent and specific rather than one of an allelic series, the phenotype is dominated by two features Baraitser-Winter does not have (infant-onset deafness and adolescent dystonia), the later reports describe it as distinct and overlapping rather than nested, and MONDO assigns a separate term. This is recorded as an open question rather than settled because it is a lump/split judgement that a reviewer may reasonably take the other way, and the remedy in that case is a has_subtypes entry on the BWCFF file.
Does the striatal lesion progress to nigrostriatal degeneration, and is the reported parkinsonism a later stage of the same process?
KNOWLEDGE GAP dystonia_progression_to_parkinsonism
Attached to
pathophysiology#Striatal Dopaminergic and Metabolic Deficit
The imaging in the best-studied patient shows a postsynaptic and metabolic striatal deficit with only a slightly abnormal presynaptic dopamine-transporter scan, which is why this entry does not conform the node to parkinsonism_dopaminergic_degeneration. A later report describes a patient who developed parkinsonism, which would be the expected finding if the presynaptic compartment is involved eventually. No patient has been imaged serially, so whether these are two stages of one process or two phenotypes is unresolved.
⚙

Pathophysiology

7
ACTB p.Arg183Trp Substitution
A recurrent heterozygous missense change at a residue adjacent to the nucleotide-binding pocket of cytoplasmic beta-actin. It is the same variant in essentially every reported patient, which is unusual enough to be worth stating: this is not an allelic series, it is one substitution.
Genetic context variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: GAIN_OF_FUNCTION
Downstream
Trapped Closed-State Actin Monomer
Show evidence (2 references)
PMID:16685646 SUPPORT Human Clinical
"We have identified a missense point mutation in the gene coding for beta -actin that results in an arginine-to-tryptophan substitution at position 183."
The identification of the variant in the original family.
PMID:25255767 SUPPORT In Vitro
"The two dominant heterozygous gain-of-function β-actin mutations p.R183W and p.E364K were identified in patients with developmental malformations, deafness and juvenile-onset dystonia (p.R183W) and neutrophil dysfunction (p.E364K)."
The source of the GAIN_OF_FUNCTION category recorded here. The authors class it that way on biochemical grounds; note the functional consequence is altered dynamics rather than increased activity in any simple sense, which is why the next node states the mechanism rather than leaving the label to carry it.
Trapped Closed-State Actin Monomer
The tryptophan stacks against Tyr69. That interaction perturbs nucleotide release from the monomer and biases it towards a closed conformation, which is what changes its polymerization behaviour. Recombinant protein work and molecular dynamics simulation agree on the mechanism. The modifier is ABNORMAL rather than DECREASED, and the reason is about export rather than about the biology. A closed nucleotide cleft retains its nucleotide, so what falls is exchange, not binding - but the bound term is GO:0000166 nucleotide binding, and kgx_export drops preferred_term and emits only the term id plus a direction qualifier. DECREASED here would put "beta-actin nucleotide binding is decreased" into the knowledge graph, which is the inverse of what the source reports. GO has no term for the exchange step itself, so the honest pairing is the binding term with a non-directional modifier.
actin nucleotide exchange GO:0000166 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves abnormal actin nucleotide exchange, annotated with nucleotide binding (GO:0000166). GO:0000166 is a molecular function from the Gene Ontology. ⚠ ABNORMAL
Downstream
Altered Actin Filament Depolymerization Dynamics
Show evidence (1 reference)
PMID:25255767 SUPPORT In Vitro
"establishes an unusual stacking interaction with Tyr69 that perturbs nucleotide release from actin monomers and polymerization behavior by inducing a closed state conformation."
The structural mechanism, from recombinant protein assays and molecular dynamics.
Altered Actin Filament Depolymerization Dynamics
The cellular readout, and the finding the disease was named from. Patient lymphoblastoid cells show a morphologically abnormal actin cytoskeleton and altered depolymerization kinetics when challenged with latrunculin A, a monomer-sequestering drug; the resistance is reproduced in fibroblasts expressing the mutant actin, so it is a property of the protein rather than of the patient's cells. The modifiers are DYSREGULATED and ABNORMAL rather than DECREASED because that is as far as the source goes: it reports "altered" depolymerization dynamics and "morphological abnormalities" of the cytoskeleton. Latrunculin resistance does suggest disassembly is harder to induce, but that reading is an inference, and the node is named for the alteration rather than for a direction.
actin filament depolymerization GO:0030042 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated actin filament depolymerization (GO:0030042). GO:0030042 is a biological process from the Gene Ontology. ↕ DYSREGULATED actin cytoskeleton organization GO:0030036 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal actin cytoskeleton organization (GO:0030036). GO:0030036 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Stereocilia Maintenance Failure Inferred for this variant. The step is supported by mouse Actb deletion in hair cells, not by any experiment on p.Arg183Trp cochlea.
Striatal Actin Turnover Failure
Neural Crest Migration Disturbance
Show evidence (2 references)
PMID:16685646 SUPPORT In Vitro
"Cellular studies of a lymphoblastoid cell line obtained from an affected patient demonstrated morphological abnormalities of the actin cytoskeleton and altered actin depolymerization dynamics in response to latrunculin A, an actin monomer-sequestering drug."
The cellular phenotype in patient-derived cells.
PMID:16685646 SUPPORT In Vitro
"Resistance to latrunculin A was also observed in NIH 3T3 cells expressing the mutant actin."
Reproduction in a heterologous cell line, which is what makes this a property of the mutant protein rather than of the patient background.
Stereocilia Maintenance Failure
The stereociliary core is an actin bundle. The mouse experiment that makes this branch credible is a negative one as much as a positive one: conditional deletion of Actb in hair cells leaves stereocilia development and young-animal hearing intact, and only produces progressive hearing loss with age. A maintenance defect rather than a developmental one is exactly what infant-onset progressive deafness from a constitutive variant needs.
cochlear auditory hair cell CL:4023120 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear auditory hair cell, annotated with cochlea auditory hair cell (CL:4023120). CL:4023120 is a cell type from the Cell Ontology.
stereocilium GO:0032420 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves stereocilium (GO:0032420). GO:0032420 is a cellular component from the Gene Ontology.
Animal models
Hair-cell conditional Actb knockout mouse Mouse partially recapitulates Establishes that beta-actin is dispensable for building stereocilia and required for keeping them, which is the development-versus-maintenance split this node depends on.
Downstream
Sensorineural hearing impairment
Show evidence (2 references)
PMID:20976199 SUPPORT Model Organism
"We found that, although cytoplasmic actin is necessary, neither β-actin nor γ-actin is required for normal stereocilia development or auditory function in young animals."
The negative half: development does not need this isoform specifically.
PMID:20976199 SUPPORT Model Organism
"However, aging mice with β-actin- or γ-actin-deficient hair cells develop different patterns of progressive hearing loss and distinct pathogenic changes in stereocilia morphology, despite colocalization of the actin isoforms."
The positive half: maintenance does. Note this is a deletion model and the human lesion is a missense change with altered dynamics, so the model supports the compartment and the developmental timing rather than the molecular mechanism.
Striatal Actin Turnover Failure
Dendritic spines are actin structures and their turnover is continuous, so a subtly abnormal actin is a chronic burden on striatal projection neurons rather than an acute one. That is the proposed reason the dystonia waits for adolescence.
medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
dendritic spine organization GO:0097061 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal dendritic spine organization (GO:0097061). GO:0097061 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Striatal Dopaminergic and Metabolic Deficit
Show evidence (1 reference)
PMID:29788902 SUPPORT INDIRECT Human Clinical
"In this patient with dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity, unprecedented brain imaging findings strongly indicate striatal neuronal/dopaminergic dysfunction as the underlying cause of the dystonia."
Locates the lesion in the striatum in a living patient. It does not establish that the cellular cause is actin turnover, which is the inferred part of this node - hence directness INDIRECT, which puts that caveat in a slot rather than only in this sentence.
Striatal Dopaminergic and Metabolic Deficit
Measured, not inferred. Epidepride-SPECT shows reduced D2-receptor binding and FDG-PET reduced glucose uptake, both bilaterally and worst in the putamen, while the presynaptic dopamine-transporter scan is only slightly abnormal. The pattern is a postsynaptic and metabolic striatal deficit rather than nigrostriatal denervation, which is why this entry does not conform the node to the parkinsonism module.
putamen UBERON:0001874 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in putamen (UBERON:0001874). UBERON:0001874 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Generalized dystonia
Show evidence (1 reference)
PMID:29788902 SUPPORT Human Clinical
"Both Epidepride-SPECT and FDG-PET showed reduced tracer uptake in the striatum bilaterally, particularly in the putamen."
The two imaging modalities and the anatomical distribution. This is the strongest in vivo human evidence in the entry.
Neural Crest Migration Disturbance
Actin-driven lamellipodial motility carries neural crest cells to the face. This is the weakest of the three branches - it is a mechanism proposed to explain the craniofacial findings, with no migration assay reported for this variant - and it is recorded at that strength.
neural crest cell CL:0011012 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neural crest cell (CL:0011012). CL:0011012 is a cell type from the Cell Ontology.
neural crest cell migration GO:0001755 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neural crest cell migration (GO:0001755). GO:0001755 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Abnormal facial shape
Show evidence (1 reference)
PMID:29788902 SUPPORT INDIRECT Human Clinical
"We hypothesize that the pleiotropic manifestations of the dystonia-deafness syndrome caused by this mutation derive from diverse developmental functions of beta-actin in neural crest migration and proliferation (facial dysmorphogenesis), hair cell stereocilia function (infant-onset deafness),..."
The proposal itself, quoted with its own hedge intact. Graded INDIRECT because the sentence is a hypothesis about what beta-actin does in the neural crest, not a measurement of migration in this variant - the node description already says no migration assay has been reported.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Developmental Malformations-Deafness-Dystonia Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Digestive 2
Dysphagia OCCASIONAL HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28487785 SUPPORT Human Clinical
"He had the subsequent onset of bulbar dystonia after our initial evaluation and this progressed to velopharyngeal insufficiency and dysphagia."
The bulbar progression stated as a sequence, which is what makes this a sequela of the generalized dystonia rather than a separate manifestation.
Achalasia OCCASIONAL HP:0002571 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Achalasia (HP:0002571). HP:0002571 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28487785 SUPPORT Human Clinical
"They initially presented with cleft lip and palate, achalasia at the age of 2 years, and mild developmental delay."
Same sentence as the cleft palate record; it lists the twins' presenting features together.
Ear 1
Sensorineural hearing impairment VERY_FREQUENT HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407), qualified as infantile onset. HP:0000407 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (1 reference)
PMID:29788902 SUPPORT Human Clinical
"ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
Records the deafness and its infant onset across the reported patients.
Head and Neck 3
Abnormal facial shape OCCASIONAL HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is mild craniofacial dysmorphism, annotated with Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16685646 SUPPORT Human Clinical
"The disease phenotype includes developmental midline malformations, sensory hearing loss, and a delayed-onset generalized dystonia syndrome in monozygotic twins."
The malformations as originally described.
PMID:28487785 REFUTE Human Clinical
"The previously reported twins with same p.Arg183Trp mutation as our patient had midline facial defects and skeletal anomalies; however our patient did not display these features of the phenotype."
Graded REFUTE against the claim that this phenotype is constant, not against the disease: the same variant in this patient produced none of the midline features the twins had. An earlier revision quoted the case-identity sentence instead and justified it by saying the abstract does not restate the negative finding. That was wrong - this cache is full_text_xml, and the sentence above is in it verbatim. The claim about what the source contains was never checked against the source.
Cleft lip OCCASIONAL HP:0410030 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cleft lip (HP:0410030), qualified as congenital onset. HP:0410030 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (1 reference)
PMID:36339314 SUPPORT Human Clinical
"He had congenital cleft lip and bilateral sensorineural deafness."
The clefting and the deafness in the same sentence, in a patient carrying the same p.Arg183Trp allele as the other reported cases.
Cleft palate OCCASIONAL HP:0000175 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cleft palate (HP:0000175), qualified as congenital onset. HP:0000175 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (1 reference)
PMID:28487785 SUPPORT Human Clinical
"They initially presented with cleft lip and palate, achalasia at the age of 2 years, and mild developmental delay."
The twins' presenting features. The same sentence is the source for the achalasia record below.
Nervous System 5
Generalized dystonia VERY_FREQUENT HP:0007325 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized dystonia (HP:0007325), qualified as course progressive; juvenile onset. HP:0007325 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: JUVENILE
Show evidence (2 references)
PMID:29788902 SUPPORT Human Clinical
"ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
Both the phenotype and its timing, across the reported series rather than a single case.
PMID:28487785 SUPPORT Human Clinical
"Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same..."
Severity, and the basal-ganglia MRI signal change that accompanies it. Also the sentence that records this case as lacking midline malformation, which is the basis for the incomplete-penetrance note below.
Absent septum pellucidum OCCASIONAL HP:0001331 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent septum pellucidum (HP:0001331). HP:0001331 is a phenotype from the Human Phenotype Ontology.
Deliberately left with no upstream pathophysiology node. The only published mechanism for the malformations in this disease is disturbed neural crest migration, and the neural crest does not form the septum pellucidum, so attaching this phenotype to that node would assert a developmental claim no source makes. The gap is recorded in the temporal_vulnerability_model_untested discussion instead.
Show evidence (1 reference)
PMID:36339314 SUPPORT Human Clinical
"Results of brain magnetic resonance imaging (MRI) were normal, except the septum pellucida was absent."
Note what the same sentence also says: the rest of the brain MRI was normal, so this patient has no basal-ganglia signal change despite severe dystonia. That is why the T2 hyperintensity below stays OCCASIONAL.
Parkinsonism OCCASIONAL HP:0001300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism (HP:0001300). HP:0001300 is a phenotype from the Human Phenotype Ontology.
PMID:36183459 names parkinsonism in its title and is the report that expanded the phenotype, but its cache is abstract_only and the abstract body does not mention parkinsonism at all - so there is nothing propositional to quote from it, and a title is not a finding. The evidence here comes from PMID:29788902 instead. The mechanistic question sits in the dystonia_progression_to_parkinsonism discussion; this record is the observation, which the discussion is not a substitute for.
Show evidence (1 reference)
PMID:29788902 SUPPORT DIRECT Human Clinical
"Some slowness and reduced amplitude of repetitive movements may represent mild signs of parkinsonism."
The examination finding, quoted with the authors' own hedge intact. "May represent mild signs" is why the band is OCCASIONAL and why the entry does not claim a parkinsonian syndrome.
Global developmental delay FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28487785 SUPPORT Human Clinical
"Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same..."
Records developmental delay alongside the two defining features.
Focal T2 hyperintense basal ganglia lesion OCCASIONAL HP:0007183 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is caudate and putaminal T2 hyperintensity, annotated with Focal T2 hyperintense basal ganglia lesion (HP:0007183). HP:0007183 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28487785 SUPPORT Human Clinical
"Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same..."
The MRI finding. Recorded as occasional because the imaging in the better-characterised later case was reported as inconclusive on structural sequences and abnormal only on functional imaging.
🧬

Genetic Associations

1
ACTB (Causative)
Gene: ACTB hgnc:132 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ACTB (hgnc:132). hgnc:132 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:16685646 SUPPORT Human Clinical
"We have identified a missense point mutation in the gene coding for beta -actin that results in an arginine-to-tryptophan substitution at position 183."
The gene-disease assignment and the variant.
PMID:25255767 SUPPORT In Vitro
"The two dominant heterozygous gain-of-function β-actin mutations p.R183W and p.E364K were identified in patients with developmental malformations, deafness and juvenile-onset dystonia (p.R183W) and neutrophil dysfunction (p.E364K)."
Supports the variant-specific framing in the notes: two ACTB variants, two unrelated phenotypes, studied side by side.
💊

Medical Actions

5
Bilateral pallidal deep brain stimulation
Action: bilateral pallidal deep brain stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is bilateral pallidal deep brain stimulation, annotated with Deep Brain Stimulation (NCIT:C21024). NCIT:C21024 is a clinical intervention from the NCI Thesaurus. Ontology label: Deep Brain Stimulation NCIT:C21024
Platform: Device
Stimulation of the postero-ventral internal pallidum. This is the only intervention in the entry with a measured outcome in this disease, and the effect is large and sustained: the Burke-Fahn-Marsden motor score fell from 87 preoperatively to 21 at 2.5 months and was still 30 at four years. A second reported patient also benefited long-term.
Mechanism Target:
Striatal Dopaminergic and Metabolic Deficit — Modulates basal-ganglia output downstream of the striatal deficit; it does not address the actin lesion.
Target Phenotypes: Generalized dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Generalized dystonia (HP:0007325). HP:0007325 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29788902 SUPPORT Human Clinical
"Pallidal stimulation provided a substantial improvement of the severe generalized dystonia, which is largely sustained at 4-year follow-up, and we advise this treatment to be considered in such patients."
The outcome and the authors' recommendation, with the four-year durability that makes it more than a short-term response.
PMID:36183459 SUPPORT Human Clinical
"Our study expands and confirms the complex phenotypic spectrum of ACTB gene-related disorders and supports the effectiveness of pallidal stimulation on motor outcomes and quality of life in dystonia due to ACTB p.Arg183Trp heterozygosity."
An independent patient with long-term benefit, which is what takes this from one case to a reproduced observation.
Bilateral subthalamic deep brain stimulation
Action: bilateral subthalamic nucleus deep brain stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is bilateral subthalamic nucleus deep brain stimulation, annotated with Deep Brain Stimulation (NCIT:C21024). NCIT:C21024 is a clinical intervention from the NCI Thesaurus. Ontology label: Deep Brain Stimulation NCIT:C21024
Platform: Device
A second, different stimulation target with its own measured outcome. The distinction from the pallidal entry above is not bookkeeping: GPi is the conventional target for generalized dystonia, and this patient was stimulated in the subthalamic nucleus instead, improving from a Burke-Fahn-Marsden motor score of 44 to 20 at twelve months. The benefit was topographically uneven - limbs far more than neck and trunk - which matters for a disease whose dystonia is generalized and whose bulbar involvement is what threatens life.
Mechanism Target:
Striatal Dopaminergic and Metabolic Deficit — As with pallidal stimulation, this modulates basal-ganglia output downstream of the striatal deficit and does not touch the actin lesion. Which node is the better target is not answerable from one patient each.
Target Phenotypes: Generalized dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Generalized dystonia (HP:0007325). HP:0007325 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36339314 SUPPORT Human Clinical
"Significant improvement of motor function (Burke‐Fahn‐Marsden's Dystonia Rating Scales–Dystonia Movement Scale ... 44 vs. 20) was observed at the 12‐month follow‐up"
The quantified outcome: the Burke-Fahn-Marsden motor score halved at one year. The ellipsis elides the source's own bracketed abbreviation of the scale name, "[BFMDRS-M]", and nothing else. It is elided rather than quoted because the reference validator strips bracketed spans from the query side only, keeping them literal just for spans matching "^[A-Z]{2,}$" - which a hyphenated abbreviation cannot match. Quoted otherwise with the source's own typography, which uses Unicode hyphens throughout.
PMID:36339314 SUPPORT Human Clinical
"The greatest BFMDRS‐M improvements were observed for the arm (66.7%) and leg (53.8%) dystonia, with less clinical impact on the neck and trunk."
The distribution of the benefit, recorded because a single summary score hides it. Arm and leg dystonia improved by roughly two thirds and one half; neck and trunk did not follow.
Oral antidystonic pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Trihexyphenidyl, then clonazepam, baclofen and pramipexole, in the one patient for whom the drug course is reported in sequence. Recorded because the entry otherwise reads as though stimulation were the only thing tried, when in practice it is what is reached for after drugs fail.
Target Phenotypes: Generalized dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Generalized dystonia (HP:0007325). HP:0007325 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36339314 REFUTE DIRECT Human Clinical
"The patient received trihexyphenidyl 4 mg daily, but during the course of up to 3 years of treatment, the efficacy was unstable, and his symptoms fluctuated. Subsequent medication with clonazepam, baclofen, and pramipexole were of limited effect."
Graded REFUTE against the claim that these agents control the dystonia, not against their being used. Three years of unstable response to trihexyphenidyl and limited effect from three further agents is the clinical context in which the stimulation result should be read.
PMID:28487785 REFUTE DIRECT Human Clinical
"DOPA-unresponsive dystonia and cognitive decline after 12 years of age"
The specifically diagnostic negative. Dopa-unresponsiveness is what separates this dystonia from dopa-responsive dystonia in a differential, so it is a stronger claim than general drug failure and belongs here rather than only in the diagnosis section.
Motor cortex deep brain stimulation
Action: motor cortex deep brain stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is motor cortex deep brain stimulation, annotated with Deep Brain Stimulation (NCIT:C21024). NCIT:C21024 is a clinical intervention from the NCI Thesaurus. Ontology label: Deep Brain Stimulation NCIT:C21024
Platform: Device
The third stimulation target tried, and the one that failed. Recorded beside the pallidal and subthalamic entries because an entry carrying only the two successful targets would read as though stimulation reliably works in this disease. It does not: this patient improved initially, then deteriorated to status dystonicus requiring a medically induced coma.
Target Phenotypes: Generalized dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Generalized dystonia (HP:0007325). HP:0007325 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28487785 SUPPORT Human Clinical
"He underwent deep brain stimulator placement in his left motor cortex, which helped to alleviate his predominately right-sided dystonia."
The intervention and its initial effect, which is why this is not simply a record of something not working.
PMID:28487785 REFUTE DIRECT Human Clinical
"Unfortunately, this was of limited benefit and he eventually suffered from status dystonicus that necessitated a medically induced coma."
Graded REFUTE against durable benefit. The two quotes together are the point: an early response that did not hold, ending in the outcome the bulbar phenotype above describes.
Cochlear device implantation
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329), qualified as medical device cochlear implant. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Device
Standard management of the infant-onset deafness, and reported in the treated patients.
Target Phenotypes: Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29788902 SUPPORT Human Clinical
"A 19-year-old girl with congenital mild dysmorphic facial features, cochlear implants for infant-onset deafness, and mild cognitive and emotional disability, presented with an adolescent-onset, severe generalized dystonia."
Records that the patient had cochlear implants. It establishes use, not outcome; no hearing outcome is reported for this genotype.
🔬

Diagnosis

1
Targeted ACTB sequencing or exome sequencing
The diagnosis has repeatedly been made late. In the best-documented case a dystonia gene panel and multiple single-gene tests were inconclusive and the variant was found only on whole-exome sequencing at age 22, three years after deep brain stimulation. The combination of infant-onset deafness with adolescent-onset dystonia is the clinical trigger that should prompt the test.
ACTB sequencing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:29788902 SUPPORT Human Clinical
"Brain MRI and multiple single gene sequencing were inconclusive."
The diagnostic odyssey this recommendation is meant to shorten: targeted testing failed and only broad sequencing found the variant.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Single figures. Six patients were counted in 2018 and a handful of further cases have been reported since, including an Argentinean family and a case with parkinsonism. No prevalence estimate exists.
Show evidence (1 reference)
PMID:29788902 SUPPORT Human Clinical
"ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
A published count as of 2018, quoted for scale rather than as a prevalence.
🐁

Animal Models

1
Hair-cell conditional Actb knockout mouse
A loss-of-function model rather than a model of p.Arg183Trp, and its value to this entry is the negative half of its result: deleting beta-actin from hair cells leaves development and young-animal hearing intact, and only produces progressive loss with age.
Species
Mouse
Genotype
Actb conditional knockout in cochlear hair cells
Publication
PMID:20976199
Pathograph links
Stereocilia Maintenance Failure partially recapitulates fidelity: moderate observes: cellular Establishes that beta-actin is dispensable for building stereocilia and required for keeping them, which is the development-versus-maintenance split this node depends on.
Limitations: A conditional null, not the human missense allele. The disease variant is heterozygous and produces an altered protein rather than none, so the model tests the requirement for beta-actin in hair cells and not the consequence of p.Arg183Trp. It also says nothing about the deafness being infant-onset in patients, where the mouse loss is age-progressive.
Show evidence (1 reference)
PMID:20976199 SUPPORT INDIRECT Model Organism
"However, aging mice with β-actin- or γ-actin-deficient hair cells develop different patterns of progressive hearing loss and distinct pathogenic changes in stereocilia morphology, despite colocalization of the actin isoforms."
The age-progressive stereocilia pathology, in the isoform this disease affects. Graded INDIRECT because it is a null allele in mouse standing in for a missense allele in human.
Notes
Recorded as an animal_models entry rather than left as inline evidence so the link to the pathograph is explicit and the translational gap is machine-readable. The two other mouse models in the research report - the global Actb knockout and the neural-crest-specific deletion - are not curated here because neither is cited in this entry and neither has been fetched; the neural-crest model in particular would be the direct model for the craniofacial branch and is worth a later round.
{ }

Source YAML

click to show 
name: Developmental Malformations-Deafness-Dystonia Syndrome
creation_date: "2026-09-11T13:05:00Z"
category: Mendelian
synonyms:
- dystonia-deafness syndrome, ACTB-related
- DDS, ACTB-related
- ACTB p.Arg183Trp syndrome
- developmental malformations, deafness, and dystonia
description: >-
  A dominant disorder of cytoplasmic beta-actin, caused in essentially every
  reported patient by the same variant: ACTB c.547C>T, p.Arg183Trp. Arginine 183
  sits beside the nucleotide-binding pocket, and replacing it with tryptophan
  creates a stacking interaction with Tyr69 that traps the monomer in a closed
  conformation, perturbing nucleotide release and polymerization. Patient cells
  are morphologically abnormal and resist latrunculin A, so the defect shows up
  as altered depolymerization dynamics rather than as absent actin.

  What makes the entry interesting is that one constitutive molecular lesion
  produces three phenotypes that appear in sequence across a lifetime -
  craniofacial dysmorphism at birth, sensorineural deafness in infancy,
  generalized dystonia in adolescence or young adulthood. The published
  explanation is a temporal-vulnerability model: beta-actin is doing different
  jobs at different stages, and each phenotype appears when the job it is failing
  at becomes rate-limiting. The deafness arm has independent support - conditional
  Actb deletion in mouse hair cells spares stereocilia development and impairs
  stereocilia maintenance, which is the same developmental-versus-maintenance
  split the human timing implies. The dystonia arm has in vivo human imaging:
  reduced striatal D2-receptor binding and reduced striatal glucose uptake.

  This is deliberately NOT curated as a subtype of Baraitser-Winter
  cerebrofrontofacial syndrome, although ACTB causes that too and
  kb/disorders/Baraitser-Winter_Cerebrofrontofacial_Syndrome.yaml already carries
  a BRWS1 subtype for the gene. The variant here is recurrent and specific, the
  original report describes the phenotype as its own entity rather than as a mild
  Baraitser-Winter, and the later series describe it as distinct and overlapping
  rather than nested. MONDO gives it a separate term. If a reviewer disagrees, the
  remedy is a has_subtypes entry on that file, and the argument should be had on
  the evidence rather than on the shared gene.

  No pathophysiology node declares conforms_to. kb/modules/ was searched for an
  actin-cytoskeleton, stereocilia-maintenance or striatal-degeneration module.
  sensorineural_hair_cell_loss is the closest and was rejected: its chain runs
  through cochlear ionic homeostasis, oxidative stress and mechanotransduction
  failure, whereas the lesion here is structural maintenance of the stereociliary
  actin core with normal development. parkinsonism_dopaminergic_degeneration was
  also read and rejected: the imaging here shows striatal postsynaptic and
  metabolic deficit with only slight nigrostriatal transporter abnormality, which
  is not that module's nigral degeneration.
disease_term:
  preferred_term: developmental malformations-deafness-dystonia syndrome
  term:
    id: MONDO:0011823
    label: developmental malformations-deafness-dystonia syndrome
parents:
- Dystonia-deafness syndrome
- Actinopathy
inheritance:
- name: Autosomal Dominant
  description: >-
    Heterozygous. Reported patients include monozygotic twins in the original
    family and subsequent apparently de novo cases.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease phenotype includes developmental midline malformations, sensory hearing loss, and a delayed-onset generalized dystonia syndrome in monozygotic twins."
    explanation: >-
      The original description. The dominant mode is in the paper's own title;
      this sentence carries the phenotype and the monozygotic-twin ascertainment.
pathophysiology:
- name: ACTB p.Arg183Trp Substitution
  biological_scale: MOLECULAR
  description: >-
    A recurrent heterozygous missense change at a residue adjacent to the
    nucleotide-binding pocket of cytoplasmic beta-actin. It is the same variant in
    essentially every reported patient, which is unusual enough to be worth
    stating: this is not an allelic series, it is one substitution.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: GAIN_OF_FUNCTION
    zygosity: HETEROZYGOUS
  evidence:
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified a missense point mutation in the gene coding for beta -actin that results in an arginine-to-tryptophan substitution at position 183."
    explanation: "The identification of the variant in the original family."
  - reference: PMID:25255767
    reference_title: "Molecular mechanisms of disease-related human β-actin mutations p.R183W and p.E364K."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The two dominant heterozygous gain-of-function β-actin mutations p.R183W and p.E364K were identified in patients with developmental malformations, deafness and juvenile-onset dystonia (p.R183W) and neutrophil dysfunction (p.E364K)."
    explanation: >-
      The source of the GAIN_OF_FUNCTION category recorded here. The authors class
      it that way on biochemical grounds; note the functional consequence is
      altered dynamics rather than increased activity in any simple sense, which
      is why the next node states the mechanism rather than leaving the label to
      carry it.
  downstream:
  - target: Trapped Closed-State Actin Monomer
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25255767
      reference_title: "Molecular mechanisms of disease-related human β-actin mutations p.R183W and p.E364K."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Arg183 is located near the nucleotide-binding pocket of actin."
      explanation: >-
        Places the substituted residue where it can act on nucleotide handling,
        which is the structural basis of this edge.
- name: Trapped Closed-State Actin Monomer
  biological_scale: MOLECULAR
  description: >-
    The tryptophan stacks against Tyr69. That interaction perturbs nucleotide
    release from the monomer and biases it towards a closed conformation, which is
    what changes its polymerization behaviour. Recombinant protein work and
    molecular dynamics simulation agree on the mechanism.

    The modifier is ABNORMAL rather than DECREASED, and the reason is about
    export rather than about the biology. A closed nucleotide cleft retains its
    nucleotide, so what falls is exchange, not binding - but the bound term is
    GO:0000166 nucleotide binding, and kgx_export drops preferred_term and emits
    only the term id plus a direction qualifier. DECREASED here would put
    "beta-actin nucleotide binding is decreased" into the knowledge graph, which
    is the inverse of what the source reports. GO has no term for the exchange
    step itself, so the honest pairing is the binding term with a
    non-directional modifier.
  molecular_functions:
  - preferred_term: actin nucleotide exchange
    modifier: ABNORMAL
    term:
      id: GO:0000166
      label: nucleotide binding
  evidence:
  - reference: PMID:25255767
    reference_title: "Molecular mechanisms of disease-related human β-actin mutations p.R183W and p.E364K."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "establishes an unusual stacking interaction with Tyr69 that perturbs nucleotide release from actin monomers and polymerization behavior by inducing a closed state conformation."
    explanation: "The structural mechanism, from recombinant protein assays and molecular dynamics."
  downstream:
  - target: Altered Actin Filament Depolymerization Dynamics
    causal_link_type: DIRECT
- name: Altered Actin Filament Depolymerization Dynamics
  biological_scale: CELLULAR
  description: >-
    The cellular readout, and the finding the disease was named from. Patient
    lymphoblastoid cells show a morphologically abnormal actin cytoskeleton and
    altered depolymerization kinetics when challenged with latrunculin A, a
    monomer-sequestering drug; the resistance is reproduced in fibroblasts
    expressing the mutant actin, so it is a property of the protein rather than of
    the patient's cells. The modifiers are DYSREGULATED and ABNORMAL rather than
    DECREASED because that is as far as the source goes: it reports "altered"
    depolymerization dynamics and "morphological abnormalities" of the
    cytoskeleton. Latrunculin resistance does suggest disassembly is harder to
    induce, but that reading is an inference, and the node is named for the
    alteration rather than for a direction.
  biological_processes:
  - preferred_term: actin filament depolymerization
    modifier: DYSREGULATED
    term:
      id: GO:0030042
      label: actin filament depolymerization
  - preferred_term: actin cytoskeleton organization
    modifier: ABNORMAL
    term:
      id: GO:0030036
      label: actin cytoskeleton organization
  evidence:
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cellular studies of a lymphoblastoid cell line obtained from an affected patient demonstrated morphological abnormalities of the actin cytoskeleton and altered actin depolymerization dynamics in response to latrunculin A, an actin monomer-sequestering drug."
    explanation: "The cellular phenotype in patient-derived cells."
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Resistance to latrunculin A was also observed in NIH 3T3 cells expressing the mutant actin."
    explanation: >-
      Reproduction in a heterologous cell line, which is what makes this a
      property of the mutant protein rather than of the patient background.
  downstream:
  - target: Stereocilia Maintenance Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Inferred for this variant. The step is supported by mouse Actb deletion in
      hair cells, not by any experiment on p.Arg183Trp cochlea.
    evidence:
    - reference: PMID:29788902
      reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We hypothesize that the pleiotropic manifestations of the dystonia-deafness syndrome caused by this mutation derive from diverse developmental functions of beta-actin in neural crest migration and proliferation (facial dysmorphogenesis), hair cell stereocilia function (infant-onset deafness), and altered synaptic activity patterns associated with pubertal changes in striatal function (adolescent-onset dystonia)."
      explanation: >-
        The temporal-vulnerability model that all three branch edges rest on. The
        authors present it as a hypothesis and this entry marks the edges indirect
        for that reason.
  - target: Striatal Actin Turnover Failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29788902
      reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We hypothesize that the pleiotropic manifestations of the dystonia-deafness syndrome caused by this mutation derive from diverse developmental functions of beta-actin in neural crest migration and proliferation (facial dysmorphogenesis), hair cell stereocilia function (infant-onset deafness), and altered synaptic activity patterns associated with pubertal changes in striatal function (adolescent-onset dystonia)."
      explanation: "Same hypothesis, the striatal branch."
  - target: Neural Crest Migration Disturbance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29788902
      reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We hypothesize that the pleiotropic manifestations of the dystonia-deafness syndrome caused by this mutation derive from diverse developmental functions of beta-actin in neural crest migration and proliferation (facial dysmorphogenesis), hair cell stereocilia function (infant-onset deafness), and altered synaptic activity patterns associated with pubertal changes in striatal function (adolescent-onset dystonia)."
      explanation: "Same hypothesis, the craniofacial branch."
- name: Stereocilia Maintenance Failure
  biological_scale: CELLULAR
  description: >-
    The stereociliary core is an actin bundle. The mouse experiment that makes
    this branch credible is a negative one as much as a positive one: conditional
    deletion of Actb in hair cells leaves stereocilia development and young-animal
    hearing intact, and only produces progressive hearing loss with age. A
    maintenance defect rather than a developmental one is exactly what infant-onset
    progressive deafness from a constitutive variant needs.
  cell_types:
  - preferred_term: cochlear auditory hair cell
    term:
      id: CL:4023120
      label: cochlea auditory hair cell
  cellular_components:
  - preferred_term: stereocilium
    term:
      id: GO:0032420
      label: stereocilium
  evidence:
  - reference: PMID:20976199
    reference_title: "β-actin and γ-actin are each dispensable for auditory hair cell development but required for Stereocilia maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found that, although cytoplasmic actin is necessary, neither β-actin nor γ-actin is required for normal stereocilia development or auditory function in young animals."
    explanation: "The negative half: development does not need this isoform specifically."
  - reference: PMID:20976199
    reference_title: "β-actin and γ-actin are each dispensable for auditory hair cell development but required for Stereocilia maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "However, aging mice with β-actin- or γ-actin-deficient hair cells develop different patterns of progressive hearing loss and distinct pathogenic changes in stereocilia morphology, despite colocalization of the actin isoforms."
    explanation: >-
      The positive half: maintenance does. Note this is a deletion model and the
      human lesion is a missense change with altered dynamics, so the model
      supports the compartment and the developmental timing rather than the
      molecular mechanism.
  downstream:
  - target: Sensorineural hearing impairment
    causal_link_type: DIRECT
- name: Striatal Actin Turnover Failure
  biological_scale: CELLULAR
  description: >-
    Dendritic spines are actin structures and their turnover is continuous, so a
    subtly abnormal actin is a chronic burden on striatal projection neurons
    rather than an acute one. That is the proposed reason the dystonia waits for
    adolescence.
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: dendritic spine organization
    modifier: ABNORMAL
    term:
      id: GO:0097061
      label: dendritic spine organization
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "In this patient with dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity, unprecedented brain imaging findings strongly indicate striatal neuronal/dopaminergic dysfunction as the underlying cause of the dystonia."
    explanation: >-
      Locates the lesion in the striatum in a living patient. It does not
      establish that the cellular cause is actin turnover, which is the inferred
      part of this node - hence directness INDIRECT, which puts that caveat in a
      slot rather than only in this sentence.
  downstream:
  - target: Striatal Dopaminergic and Metabolic Deficit
    causal_link_type: DIRECT
- name: Striatal Dopaminergic and Metabolic Deficit
  biological_scale: TISSUE
  description: >-
    Measured, not inferred. Epidepride-SPECT shows reduced D2-receptor binding and
    FDG-PET reduced glucose uptake, both bilaterally and worst in the putamen,
    while the presynaptic dopamine-transporter scan is only slightly abnormal. The
    pattern is a postsynaptic and metabolic striatal deficit rather than
    nigrostriatal denervation, which is why this entry does not conform the node to
    the parkinsonism module.
  locations:
  - preferred_term: putamen
    term:
      id: UBERON:0001874
      label: putamen
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both Epidepride-SPECT and FDG-PET showed reduced tracer uptake in the striatum bilaterally, particularly in the putamen."
    explanation: >-
      The two imaging modalities and the anatomical distribution. This is the
      strongest in vivo human evidence in the entry.
  downstream:
  - target: Generalized dystonia
    causal_link_type: DIRECT
- name: Neural Crest Migration Disturbance
  biological_scale: CELLULAR
  description: >-
    Actin-driven lamellipodial motility carries neural crest cells to the face.
    This is the weakest of the three branches - it is a mechanism proposed to
    explain the craniofacial findings, with no migration assay reported for this
    variant - and it is recorded at that strength.
  cell_types:
  - preferred_term: neural crest cell
    term:
      id: CL:0011012
      label: neural crest cell
  biological_processes:
  - preferred_term: neural crest cell migration
    modifier: ABNORMAL
    term:
      id: GO:0001755
      label: neural crest cell migration
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "We hypothesize that the pleiotropic manifestations of the dystonia-deafness syndrome caused by this mutation derive from diverse developmental functions of beta-actin in neural crest migration and proliferation (facial dysmorphogenesis), hair cell stereocilia function (infant-onset deafness), and altered synaptic activity patterns associated with pubertal changes in striatal function (adolescent-onset dystonia)."
    explanation: >-
      The proposal itself, quoted with its own hedge intact. Graded INDIRECT
      because the sentence is a hypothesis about what beta-actin does in the
      neural crest, not a measurement of migration in this variant - the node
      description already says no migration assay has been reported.
  downstream:
  - target: Abnormal facial shape
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- category: Neurologic
  name: Generalized dystonia
  description: >-
    Onset in adolescence or young adulthood, progressive, and often severe enough
    to be life-threatening. Bulbar involvement with velopharyngeal insufficiency
    and dysphagia is reported.
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
    clinical_course: PROGRESSIVE
    onset:
      onset_category: JUVENILE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
    explanation: >-
      Both the phenotype and its timing, across the reported series rather than a
      single case.
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same alteration in ACTB."
    explanation: >-
      Severity, and the basal-ganglia MRI signal change that accompanies it. Also
      the sentence that records this case as lacking midline malformation, which
      is the basis for the incomplete-penetrance note below.
- category: Auditory
  name: Sensorineural hearing impairment
  description: >-
    Infant-onset, and typically the first manifestation. Cochlear implantation is
    the usual management.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
    onset:
      onset_category: INFANTILE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
    explanation: "Records the deafness and its infant onset across the reported patients."
- category: Craniofacial
  name: Abnormal facial shape
  description: >-
    Mild dysmorphic features, and the least consistent of the three phenotypes.
    The original twins had developmental midline malformations; a later patient
    with the identical variant was explicitly non-dysmorphic.
  phenotype_term:
    preferred_term: mild craniofacial dysmorphism
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease phenotype includes developmental midline malformations, sensory hearing loss, and a delayed-onset generalized dystonia syndrome in monozygotic twins."
    explanation: "The malformations as originally described."
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The previously reported twins with same p.Arg183Trp mutation as our patient had midline facial defects and skeletal anomalies; however our patient did not display these features of the phenotype."
    explanation: >-
      Graded REFUTE against the claim that this phenotype is constant, not
      against the disease: the same variant in this patient produced none of the
      midline features the twins had. An earlier revision quoted the
      case-identity sentence instead and justified it by saying the abstract does
      not restate the negative finding. That was wrong - this cache is
      full_text_xml, and the sentence above is in it verbatim. The claim about
      what the source contains was never checked against the source.
- category: Craniofacial
  name: Cleft lip
  description: >-
    A specific orofacial cleft in one reported patient, repaired surgically.
    Curated separately from the general dysmorphism record because a cleft is a
    discrete failure of facial prominence fusion rather than a description of
    facial shape.
  phenotype_term:
    preferred_term: Cleft lip
    term:
      id: HP:0410030
      label: Cleft lip
    onset:
      onset_category: CONGENITAL
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36339314
    reference_title: "Dystonia-Deafness Syndrome Response to Subthalamic Nucleus Stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had congenital cleft lip and bilateral sensorineural deafness."
    explanation: >-
      The clefting and the deafness in the same sentence, in a patient carrying
      the same p.Arg183Trp allele as the other reported cases.
- category: Neurologic
  name: Absent septum pellucidum
  description: >-
    A midline forebrain malformation, found incidentally on an MRI that was
    otherwise normal. Worth its own record because the "developmental
    malformations" in this disease's name are midline malformations, and this
    is the one reported instance with a specific anatomical diagnosis rather
    than a general statement.
  phenotype_term:
    preferred_term: Absent septum pellucidum
    term:
      id: HP:0001331
      label: Absent septum pellucidum
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36339314
    reference_title: "Dystonia-Deafness Syndrome Response to Subthalamic Nucleus Stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results of brain magnetic resonance imaging (MRI) were normal, except the septum pellucida was absent."
    explanation: >-
      Note what the same sentence also says: the rest of the brain MRI was
      normal, so this patient has no basal-ganglia signal change despite
      severe dystonia. That is why the T2 hyperintensity below stays
      OCCASIONAL.
  notes: >-
    Deliberately left with no upstream pathophysiology node. The only published
    mechanism for the malformations in this disease is disturbed neural crest
    migration, and the neural crest does not form the septum pellucidum, so
    attaching this phenotype to that node would assert a developmental claim no
    source makes. The gap is recorded in the
    temporal_vulnerability_model_untested discussion instead.
- category: Neurologic
  name: Parkinsonism
  description: >-
    Reported alongside the dystonia in more than one patient, and hedged in both
    places. The best-characterised case shows bradykinetic features on
    examination rather than a diagnosed parkinsonian syndrome; a later report
    puts parkinsonism in its title. Whether this is a second phenotype or a
    later stage of the same striatal lesion is recorded as a knowledge gap.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some slowness and reduced amplitude of repetitive movements may represent mild signs of parkinsonism."
    explanation: >-
      The examination finding, quoted with the authors' own hedge intact. "May
      represent mild signs" is why the band is OCCASIONAL and why the entry does
      not claim a parkinsonian syndrome.
  notes: >-
    PMID:36183459 names parkinsonism in its title and is the report that
    expanded the phenotype, but its cache is abstract_only and the abstract body
    does not mention parkinsonism at all - so there is nothing propositional to
    quote from it, and a title is not a finding. The evidence here comes from
    PMID:29788902 instead. The mechanistic question sits in the
    dystonia_progression_to_parkinsonism discussion; this record is the
    observation, which the discussion is not a substitute for.
- category: Gastrointestinal
  name: Dysphagia
  description: >-
    A consequence of bulbar dystonia rather than an independent feature, and the
    one that carries the mortality: in the reported case it progressed to
    velopharyngeal insufficiency and then to status dystonicus requiring a
    medically induced coma.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had the subsequent onset of bulbar dystonia after our initial evaluation and this progressed to velopharyngeal insufficiency and dysphagia."
    explanation: >-
      The bulbar progression stated as a sequence, which is what makes this a
      sequela of the generalized dystonia rather than a separate manifestation.
- category: Craniofacial
  name: Cleft palate
  description: >-
    Present with the cleft lip in the original twins. Curated separately because
    a palatal cleft is a distinct fusion event from a labial one, and because
    the entry already carries cleft lip alone from a different patient.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
    onset:
      onset_category: CONGENITAL
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They initially presented with cleft lip and palate, achalasia at the age of 2 years, and mild developmental delay."
    explanation: >-
      The twins' presenting features. The same sentence is the source for the
      achalasia record below.
- category: Gastrointestinal
  name: Achalasia
  description: >-
    Reported at age 2 in the original twins and not since. Recorded because an
    oesophageal motility disorder in an actinopathy is mechanistically
    suggestive - smooth-muscle and enteric neuronal function both depend on the
    cytoskeleton - but nothing in the cited literature tests that, so the entry
    carries the observation without an upstream node.
  phenotype_term:
    preferred_term: Achalasia
    term:
      id: HP:0002571
      label: Achalasia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They initially presented with cleft lip and palate, achalasia at the age of 2 years, and mild developmental delay."
    explanation: >-
      Same sentence as the cleft palate record; it lists the twins' presenting
      features together.
- category: Neurologic
  name: Global developmental delay
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: FREQUENT
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same alteration in ACTB."
    explanation: "Records developmental delay alongside the two defining features."
- category: Neurologic
  name: Focal T2 hyperintense basal ganglia lesion
  description: >-
    Symmetrical signal change in the caudate and putamen, the imaging correlate of
    the striatal lesion.
  phenotype_term:
    preferred_term: caudate and putaminal T2 hyperintensity
    term:
      id: HP:0007183
      label: Focal T2 hyperintense basal ganglia lesion
  frequency: OCCASIONAL
  diagnostic: true
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same alteration in ACTB."
    explanation: >-
      The MRI finding. Recorded as occasional because the imaging in the
      better-characterised later case was reported as inconclusive on structural
      sequences and abnormal only on functional imaging.
genetic:
- name: ACTB
  gene_term:
    preferred_term: ACTB
    term:
      id: hgnc:132
      label: ACTB
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Heterozygous c.547C>T, p.Arg183Trp, in essentially every reported patient.
    ACTB is highly pleiotropic: other variants cause Baraitser-Winter
    cerebrofrontofacial syndrome type 1 (curated separately), and p.Glu364Lys
    causes a neutrophil dysfunction phenotype. The three are separated by variant
    and by mechanism rather than by gene, which is why this record is
    variant-specific and says so.
  evidence:
  - reference: PMID:16685646
    reference_title: "A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified a missense point mutation in the gene coding for beta -actin that results in an arginine-to-tryptophan substitution at position 183."
    explanation: "The gene-disease assignment and the variant."
  - reference: PMID:25255767
    reference_title: "Molecular mechanisms of disease-related human β-actin mutations p.R183W and p.E364K."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The two dominant heterozygous gain-of-function β-actin mutations p.R183W and p.E364K were identified in patients with developmental malformations, deafness and juvenile-onset dystonia (p.R183W) and neutrophil dysfunction (p.E364K)."
    explanation: >-
      Supports the variant-specific framing in the notes: two ACTB variants, two
      unrelated phenotypes, studied side by side.
animal_models:
- name: Hair-cell conditional Actb knockout mouse
  species: Mouse
  genotype: Actb conditional knockout in cochlear hair cells
  publication: PMID:20976199
  description: >-
    A loss-of-function model rather than a model of p.Arg183Trp, and its value
    to this entry is the negative half of its result: deleting beta-actin from
    hair cells leaves development and young-animal hearing intact, and only
    produces progressive loss with age.
  modeled_mechanisms:
  - target: Stereocilia Maintenance Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Establishes that beta-actin is dispensable for building stereocilia and
      required for keeping them, which is the development-versus-maintenance
      split this node depends on.
    limitations: >-
      A conditional null, not the human missense allele. The disease variant is
      heterozygous and produces an altered protein rather than none, so the
      model tests the requirement for beta-actin in hair cells and not the
      consequence of p.Arg183Trp. It also says nothing about the deafness being
      infant-onset in patients, where the mouse loss is age-progressive.
    evidence:
    - reference: PMID:20976199
      reference_title: "β-actin and γ-actin are each dispensable for auditory hair cell development but required for Stereocilia maintenance."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "However, aging mice with β-actin- or γ-actin-deficient hair cells develop different patterns of progressive hearing loss and distinct pathogenic changes in stereocilia morphology, despite colocalization of the actin isoforms."
      explanation: >-
        The age-progressive stereocilia pathology, in the isoform this disease
        affects. Graded INDIRECT because it is a null allele in mouse standing
        in for a missense allele in human.
  notes: >-
    Recorded as an animal_models entry rather than left as inline evidence so
    the link to the pathograph is explicit and the translational gap is
    machine-readable. The two other mouse models in the research report - the
    global Actb knockout and the neural-crest-specific deletion - are not
    curated here because neither is cited in this entry and neither has been
    fetched; the neural-crest model in particular would be the direct model for
    the craniofacial branch and is worth a later round.

treatments:
- name: Bilateral pallidal deep brain stimulation
  description: >-
    Stimulation of the postero-ventral internal pallidum. This is the only
    intervention in the entry with a measured outcome in this disease, and the
    effect is large and sustained: the Burke-Fahn-Marsden motor score fell from 87
    preoperatively to 21 at 2.5 months and was still 30 at four years. A second
    reported patient also benefited long-term.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: bilateral pallidal deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Striatal Dopaminergic and Metabolic Deficit
    description: >-
      Modulates basal-ganglia output downstream of the striatal deficit; it does
      not address the actin lesion.
  target_phenotypes:
  - preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pallidal stimulation provided a substantial improvement of the severe generalized dystonia, which is largely sustained at 4-year follow-up, and we advise this treatment to be considered in such patients."
    explanation: >-
      The outcome and the authors' recommendation, with the four-year durability
      that makes it more than a short-term response.
  - reference: PMID:36183459
    reference_title: "ACTB gene mutation in combined Dystonia-Deafness syndrome with parkinsonism: Expanding the phenotype and highlighting the long-term GPi DBS outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study expands and confirms the complex phenotypic spectrum of ACTB gene-related disorders and supports the effectiveness of pallidal stimulation on motor outcomes and quality of life in dystonia due to ACTB p.Arg183Trp heterozygosity."
    explanation: >-
      An independent patient with long-term benefit, which is what takes this from
      one case to a reproduced observation.
  notes: >-
    Two patients, both reported by the teams that treated them. That is the whole
    evidence base; it is recorded as such rather than as an established therapy.
- name: Bilateral subthalamic deep brain stimulation
  description: >-
    A second, different stimulation target with its own measured outcome. The
    distinction from the pallidal entry above is not bookkeeping: GPi is the
    conventional target for generalized dystonia, and this patient was
    stimulated in the subthalamic nucleus instead, improving from a
    Burke-Fahn-Marsden motor score of 44 to 20 at twelve months. The benefit
    was topographically uneven - limbs far more than neck and trunk - which
    matters for a disease whose dystonia is generalized and whose bulbar
    involvement is what threatens life.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: bilateral subthalamic nucleus deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Striatal Dopaminergic and Metabolic Deficit
    description: >-
      As with pallidal stimulation, this modulates basal-ganglia output
      downstream of the striatal deficit and does not touch the actin lesion.
      Which node is the better target is not answerable from one patient each.
  target_phenotypes:
  - preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  evidence:
  - reference: PMID:36339314
    reference_title: "Dystonia-Deafness Syndrome Response to Subthalamic Nucleus Stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant improvement of motor function (Burke‐Fahn‐Marsden's Dystonia Rating Scales–Dystonia Movement Scale ... 44 vs. 20) was observed at the 12‐month follow‐up"
    explanation: >-
      The quantified outcome: the Burke-Fahn-Marsden motor score halved at one
      year. The ellipsis elides the source's own bracketed abbreviation of the
      scale name, "[BFMDRS-M]", and nothing else. It is elided rather than
      quoted because the reference validator strips bracketed spans from the
      query side only, keeping them literal just for spans matching
      "^[A-Z]{2,}$" - which a hyphenated abbreviation cannot match. Quoted
      otherwise with the source's own typography, which uses Unicode hyphens
      throughout.
  - reference: PMID:36339314
    reference_title: "Dystonia-Deafness Syndrome Response to Subthalamic Nucleus Stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The greatest BFMDRS‐M improvements were observed for the arm (66.7%) and leg (53.8%) dystonia, with less clinical impact on the neck and trunk."
    explanation: >-
      The distribution of the benefit, recorded because a single summary score
      hides it. Arm and leg dystonia improved by roughly two thirds and one
      half; neck and trunk did not follow.
  notes: >-
    One patient, reported by the team that treated him. It is curated as a
    separate treatment from pallidal stimulation rather than folded into a
    generic "deep brain stimulation" record because the target is different
    and the evidence for each is a single-digit number of patients - merging
    them would make the combined evidence look stronger than either.
- name: Oral antidystonic pharmacotherapy
  description: >-
    Trihexyphenidyl, then clonazepam, baclofen and pramipexole, in the one
    patient for whom the drug course is reported in sequence. Recorded because
    the entry otherwise reads as though stimulation were the only thing tried,
    when in practice it is what is reached for after drugs fail.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  evidence:
  - reference: PMID:36339314
    reference_title: "Dystonia-Deafness Syndrome Response to Subthalamic Nucleus Stimulation."
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient received trihexyphenidyl 4 mg daily, but during the course of up to 3 years of treatment, the efficacy was unstable, and his symptoms fluctuated. Subsequent medication with clonazepam, baclofen, and pramipexole were of limited effect."
    explanation: >-
      Graded REFUTE against the claim that these agents control the dystonia,
      not against their being used. Three years of unstable response to
      trihexyphenidyl and limited effect from three further agents is the
      clinical context in which the stimulation result should be read.
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "DOPA-unresponsive dystonia and cognitive decline after 12 years of age"
    explanation: >-
      The specifically diagnostic negative. Dopa-unresponsiveness is what
      separates this dystonia from dopa-responsive dystonia in a differential,
      so it is a stronger claim than general drug failure and belongs here
      rather than only in the diagnosis section.
  notes: >-
    No trial exists. This is one patient's drug history, and its value is as
    the comparator for the stimulation outcome in the same patient rather than
    as an efficacy claim about any of the four agents.
- name: Motor cortex deep brain stimulation
  description: >-
    The third stimulation target tried, and the one that failed. Recorded
    beside the pallidal and subthalamic entries because an entry carrying only
    the two successful targets would read as though stimulation reliably works
    in this disease. It does not: this patient improved initially, then
    deteriorated to status dystonicus requiring a medically induced coma.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: motor cortex deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_phenotypes:
  - preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  evidence:
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He underwent deep brain stimulator placement in his left motor cortex, which helped to alleviate his predominately right-sided dystonia."
    explanation: >-
      The intervention and its initial effect, which is why this is not simply
      a record of something not working.
  - reference: PMID:28487785
    reference_title: "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation."
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unfortunately, this was of limited benefit and he eventually suffered from status dystonicus that necessitated a medically induced coma."
    explanation: >-
      Graded REFUTE against durable benefit. The two quotes together are the
      point: an early response that did not hold, ending in the outcome the
      bulbar phenotype above describes.
  notes: >-
    One patient. Kept as a separate treatment from the pallidal and subthalamic
    records for the same reason those two are separate from each other - the
    target differs, the evidence for each is a single-digit number of patients,
    and merging them would make deep brain stimulation look like one
    intervention with a mixed record rather than three targets with three
    separate and very thin evidence bases.
- name: Cochlear device implantation
  description: >-
    Standard management of the infant-onset deafness, and reported in the treated
    patients.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: cochlear implant
        term:
          id: NCIT:C157820
          label: Cochlear Implant
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 19-year-old girl with congenital mild dysmorphic facial features, cochlear implants for infant-onset deafness, and mild cognitive and emotional disability, presented with an adolescent-onset, severe generalized dystonia."
    explanation: >-
      Records that the patient had cochlear implants. It establishes use, not
      outcome; no hearing outcome is reported for this genotype.
diagnosis:
- name: Targeted ACTB sequencing or exome sequencing
  description: >-
    The diagnosis has repeatedly been made late. In the best-documented case a
    dystonia gene panel and multiple single-gene tests were inconclusive and the
    variant was found only on whole-exome sequencing at age 22, three years after
    deep brain stimulation. The combination of infant-onset deafness with
    adolescent-onset dystonia is the clinical trigger that should prompt the test.
  diagnosis_term:
    preferred_term: ACTB sequencing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI and multiple single gene sequencing were inconclusive."
    explanation: >-
      The diagnostic odyssey this recommendation is meant to shorten: targeted
      testing failed and only broad sequencing found the variant.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Single figures. Six patients were counted in 2018 and a handful of further
    cases have been reported since, including an Argentinean family and a case
    with parkinsonism. No prevalence estimate exists.
  evidence:
  - reference: PMID:29788902
    reference_title: "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ACTB p.Arg183Trp heterozygosity has been reported in six patients to cause combined infant-onset deafness and dystonia manifesting in adolescence or young adulthood."
    explanation: "A published count as of 2018, quoted for scale rather than as a prevalence."
discussions:
- discussion_id: temporal_vulnerability_model_untested
  kind: KNOWLEDGE_GAP
  prompt: >-
    Is the sequential appearance of craniofacial, auditory and striatal phenotypes
    really explained by stage-specific beta-actin requirements, and does gamma-actin
    upregulation buffer it?
  attaches_to:
  - pathophysiology#Altered Actin Filament Depolymerization Dynamics
  - pathophysiology#Stereocilia Maintenance Failure
  - pathophysiology#Striatal Actin Turnover Failure
  - pathophysiology#Neural Crest Migration Disturbance
  - phenotypes#Absent septum pellucidum
  rationale: >-
    All three branch edges in this pathograph rest on one hypothesis stated in one
    paper, and the entry marks them INDIRECT_UNKNOWN_INTERMEDIATES for that reason.
    The model is attractive and partly corroborated - the mouse stereocilia work
    independently shows a development-versus-maintenance split in the right
    direction - but nothing has tested it for p.Arg183Trp in any tissue. The
    proposed buffering by gamma-actin upregulation would explain why monozygotic
    twins and an unrelated case with the identical variant differ in whether they
    have midline malformations at all, and it has not been measured in patient
    tissue either.

    There is also a malformation the hypothesis does not reach at all. A third
    patient has an absent septum pellucidum on an otherwise normal brain MRI.
    The septum pellucidum is a midline forebrain derivative, not a neural crest
    derivative, so the craniofacial branch of this model cannot account for it
    and this entry leaves that phenotype without an upstream node. Since
    "developmental malformations" is the first word of the disease name, a
    mechanism that explains the face but not the midline CNS is an incomplete
    account rather than a nearly complete one.
- discussion_id: separate_entity_versus_bwcff_subtype
  kind: KNOWLEDGE_GAP
  prompt: >-
    Should this be a separate disease entry or a has_subtypes entry on
    Baraitser-Winter cerebrofrontofacial syndrome?
  attaches_to:
  - disease#Developmental Malformations-Deafness-Dystonia Syndrome
  rationale: >-
    ACTB causes both, kb/disorders/Baraitser-Winter_Cerebrofrontofacial_Syndrome.yaml
    already carries a BRWS1 subtype for the gene, and one reported patient here had
    mild dysmorphic features that would not look out of place there. The case for
    separation is that the variant is recurrent and specific rather than one of an
    allelic series, the phenotype is dominated by two features Baraitser-Winter does
    not have (infant-onset deafness and adolescent dystonia), the later reports
    describe it as distinct and overlapping rather than nested, and MONDO assigns a
    separate term. This is recorded as an open question rather than settled because
    it is a lump/split judgement that a reviewer may reasonably take the other way,
    and the remedy in that case is a has_subtypes entry on the BWCFF file.
- discussion_id: dystonia_progression_to_parkinsonism
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does the striatal lesion progress to nigrostriatal degeneration, and is the
    reported parkinsonism a later stage of the same process?
  attaches_to:
  - pathophysiology#Striatal Dopaminergic and Metabolic Deficit
  rationale: >-
    The imaging in the best-studied patient shows a postsynaptic and metabolic
    striatal deficit with only a slightly abnormal presynaptic dopamine-transporter
    scan, which is why this entry does not conform the node to
    parkinsonism_dopaminergic_degeneration. A later report describes a patient who
    developed parkinsonism, which would be the expected finding if the presynaptic
    compartment is involved eventually. No patient has been imaged serially, so
    whether these are two stages of one process or two phenotypes is unresolved.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Self-review: consume PMID:36339314 — STN-DBS, drug failure, cleft lip, absent septum pellucidum · 2026-09-11T14:14:42Z · View source

Self-review round run while claude-review was unavailable (shared Claude account usage limit, resets 2026-09-12T20:00Z). I applied to this entry the finding shape the automated reviewer had raised on the other PRs in this batch - a deep-research source present in the report and absent from the YAML - and found three such sources. Two of the three are not usable: PMID:31970217 and PMID:35005077 are both Movement Disorders Clinical Practice case reports with no abstract in PubMed and no open full text, so their fetched caches are empty and nothing in them is quotable. They were fetched, inspected, and the empty cache files deleted rather than committed. The third, PMID:36339314, is substantial and produced four additions: - Bilateral subthalamic deep brain stimulation, curated as a treatment separate from the existing pallidal entry. The target is different - STN, not GPi - and the outcome is quantified (Burke-Fahn-Marsden motor score 44 to 20 at twelve months, with arm and leg improving far more than neck and trunk). Kept separate rather than merged into a generic DBS record because each target rests on one or two patients and merging would make the combined evidence look stronger than either. - Oral antidystonic pharmacotherapy, graded REFUTE against the claim that these agents control the dystonia: three years of unstable response to trihexyphenidyl and limited effect from clonazepam, baclofen and pramipexole. Added because the entry previously read as though stimulation were the only thing tried. - Cleft lip (HP:0410030), curated separately from the general Abnormal facial shape record because a cleft is a discrete fusion failure rather than a description of facial shape. - Absent septum pellucidum (HP:0001331), deliberately left with no upstream pathophysiology node. The only published mechanism for the malformations here is disturbed neural crest migration, and the septum pellucidum is a midline forebrain derivative rather than a neural crest derivative, so attaching it would assert a developmental claim no source makes. The temporal_vulnerability_model_untested discussion now records this explicitly: the hypothesis explains the face and not the midline CNS, which matters for a disease whose name begins with developmental malformations. One tooling note, recorded in the evidence explanation itself. The headline outcome sentence contains the source's own bracketed abbreviation of the rating scale. The reference validator strips bracketed spans from the query side and keeps literal only spans matching ^[A-Z]{2,}$, which a hyphenated abbreviation cannot match, so the verbatim quote failed. The snippet uses an ellipsis eliding exactly that bracket and nothing else, and says so. The config pattern was not widened, since CLAUDE.md asks for a whole-KB replay before changing it. Validation: just validate-disorders (schema, terms, 34/34 snippets); check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values, check-snippet-grading, check-title-snippets, check-snippet-length, check-reference-titles, check-environmental-evidence, check-folded-hyphens all clean; bulk OLS id/label comparison over 26 pairs, 0 mismatches. Cache diff is two lines.

Create: Developmental_Malformations-Deafness-Dystonia_Syndrome · 2026-09-11T13:05:27Z · View source

De novo curation of developmental malformations-deafness-dystonia syndrome (MONDO:0011823, ACTB p.Arg183Trp). DEEP-RESEARCH PROVIDER: the brief asked for perplexity; the account quota was exhausted mid-run (HTTP 401 insufficient_quota). The run was re-issued with just dr_fallback='--fallback' rather than substituting a provider by hand, and the handover is recorded in the report frontmatter (requested_provider perplexity, fell_back true, provider_attempts perplexity/falcon/claude_code). Report: research/Developmental_Malformations-Deafness-Dystonia_Syndrome-deep-research-claude_code.md, 24 citations. The report earned its place: PMID:16685646, the 2006 paper that first identified the variant and did the latrunculin A work, and PMID:20976199, the conditional Actb hair-cell deletion study, were both absent from my relevance-sorted PubMed searches and are now the backbone of the molecular and auditory arms respectively. Report validation read before use. reference_validation: 13/13 resolved but quotes_valid 1 of 5, with unsupported quotes attributed to PMID:28487785 and PMC:PMC5405358. No quoted material was taken from the report; every snippet here was copied from references_cache and verified. term_validation: 2 of 12 labels mismatched (HP:0025230 offered as 'Dystonic tremor' when HPO calls it Tendonitis; NCIT:C1364 as 'Botulinum Toxin' when NCIT calls it Didemnin B). No CURIE was taken from the report; all bindings were looked up in the same step they were written and then re-checked in bulk with a per-file id/label comparison against OLS before validation. LUMP/SPLIT DECISION. Curated as a separate Disease rather than a has_subtypes entry on Baraitser-Winter_Cerebrofrontofacial_Syndrome, which already carries a BRWS1 subtype for ACTB. Grounds: the variant is recurrent and specific rather than one of an allelic series; the phenotype is dominated by two features Baraitser-Winter does not have; the later reports describe it as distinct and overlapping rather than nested; MONDO assigns a separate term. Recorded as an open discussion rather than presented as settled, with the alternative remedy named, because it is a judgement a reviewer may reasonably take the other way. All three branch edges from the cellular node are marked INDIRECT_UNKNOWN_INTERMEDIATES. They rest on one temporal-vulnerability hypothesis stated in one paper, and the entry says so rather than asserting stage-specific mechanisms as demonstrated. The auditory branch has independent mouse support for the development-versus-maintenance split but not for this variant. One evidence item is graded REFUTE: PMID:28487785 against the claim that craniofacial dysmorphism is constant in this disease, since that paper reports the identical variant WITHOUT midline malformation. The explanation states explicitly that it refutes the constancy of the phenotype and not the disease. No conforms_to. sensorineural_hair_cell_loss and parkinsonism_dopaminergic_degeneration were both read and rejected, with the reasons written into the entry description rather than left as omissions. One validation failure: 'located_in' is a Descriptor slot and is not available on Pathophysiology; the correct slot is 'locations'. Validated with just validate (schema, terms, 29/29 snippets), check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values, check-snippet-grading.

Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-sonnet-5 24 citations 2026-09-11T12:55:12.990285

1. Disease Information

Overview. Developmental malformations–deafness–dystonia syndrome — synonymous with Dystonia-Deafness Syndrome 1 (DDS1) — is an ultra-rare autosomal dominant neurodevelopmental/neurodegenerative disorder caused by heterozygous missense variants in ACTB (cytoplasmic β-actin). It is defined by the triad of (variable) midline/craniofacial developmental malformations, congenital or infancy-onset bilateral sensorineural hearing loss, and delayed-onset (childhood-to-adult) progressive generalized dystonia, often evolving to a severe, life-threatening motor disorder (Orphanet; OMIM #607371).

Key identifiers: - OMIM phenotype: #607371 — DYSTONIA-DEAFNESS SYNDROME 1 (DDS1) - OMIM gene: 102630 — ACTIN, BETA (ACTB) - MONDO: MONDO:0011823 - Orphanet: ORPHA:79107 - ICD-10: Q87.8 (other specified congenital malformation syndromes); ICD-11: classified among syndromic genetic deafness/developmental defects of embryogenesis - HGNC: HGNC:132 (ACTB); NCBI Gene: 60 (human ACTB), located 7p22.1 - UMLS/GTR concept: C5848323 - MalaCards / GARD ID:* 9818

Synonyms/alternative names: Dystonia-deafness syndrome (DDS); DDS1; Deafness-dystonia syndrome due to β-actin mutation; ACTB-related dystonia-deafness syndrome. (Note: this is distinct from Mohr-Tranebjaerg syndrome / deafness-dystonia-optic neuronopathy, TIMM8A/X-linked, OMIM #304700; from BCAP31-related "deafness, dystonia, and cerebral hypomyelination," OMIM #300475, X-linked; and from MEGDEL syndrome/SERAC1-related 3-methylglutaconic aciduria type VI with deafness-dystonia, OMIM #614739, autosomal recessive mitochondrial — all of which share the "deafness + dystonia" phenotype family but are genetically and mechanistically distinct.)

Evidence basis: This is one of the rarest known Mendelian disorders — described in aggregate literature review as fewer than 10–15 published families/cases worldwide, most sharing a single recurrent missense variant. Information is derived overwhelmingly from individual case reports and small case series (n=1 to n=7), not aggregated registry/EHR data; there is no disease registry or large cohort study.

Sources: Orphanet 79107; OMIM #607371; GARD; MalaCards

2. Etiology

Disease causal factor — genetic, monogenic. DDS1 is caused by heterozygous, typically de novo, missense mutations in ACTB, encoding cytoplasmic β-actin. There is no known environmental, infectious, or purely mechanistic (non-genetic) causal pathway; this is a pure Mendelian actinopathy.

Causal/recurrent variant: The dominant recurrent pathogenic variant across nearly all reported cases is NM_001101.5(ACTB):c.547C>T, p.(Arg183Trp), first reported by Procaccio et al. (2006) in monozygotic twin brothers (PMID:16685646). As of the most recent case series (Vermeulen et al. 2018), it had been reported in six unrelated cases; subsequent case reports (2020, 2021, 2022, 2025) have expanded this to roughly a dozen documented individuals/families.

"A mutation of β-actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia" — title of the founding report, Procaccio et al., Am J Hum Genet 2006;78(6):947–60 (PMID:16685646).

Arg183 lies in the ATP-binding pocket of β-actin and is highly evolutionarily conserved; the R183W substitution destabilizes the nucleotide-binding cleft, producing an actin monomer with abnormal (decreased) polymerization/depolymerization kinetics in both recombinant protein assays and patient-derived cells.

Genetic risk factors: - Causal variant: ACTB c.547C>T p.Arg183Trp (the dominant recurrent allele) - De novo occurrence is the most common inheritance mechanism reported (confirmed in multiple trios via exome sequencing), though vertical transmission (affected mother → affected daughter, and a multi-generation Argentinean family) has also been documented, consistent with autosomal dominant inheritance with full-to-high penetrance (PMID:35005077; Vermeulen et al. PMID:29788902). - No established modifier genes, but γ-actin (ACTG1) upregulation is proposed as a partial genetic compensator modulating phenotypic severity and tissue-specific timing (see Mechanism, below). - Allelic disorders: other, distinct ACTB missense variants (most commonly the recurrent p.Arg196His) cause Baraitser-Winter cerebrofrontofacial syndrome type 1 (BRWS1), a phenotypically overlapping but mechanistically distinguishable actinopathy with more prominent brain malformation (pachygyria) and craniofacial dysmorphism (PMC3677859; PMC12443469). 7p22.1 microdeletions encompassing ACTB cause a contiguous-gene developmental-delay/microcephaly/short-stature phenotype, distinct from DDS1.

Environmental risk/protective factors: None reported or plausible — this is a fully penetrant structural-protein Mendelian disorder with no documented gene-environment interaction literature.

Protective factors: None established. The hypothesized "protective" factor is endogenous — compensatory γ-actin (ACTG1) upregulation, which is proposed to explain incomplete penetrance of certain features and inter-individual phenotypic variability, but this is a molecular buffering mechanism rather than a modifiable protective exposure (PMID:29788902).

3. Phenotypes

The phenotype unfolds in an age-dependent sequence reflecting β-actin's differing tissue roles across development (see also Mechanism, §6).

Phenotype Type Onset Frequency (of reported cases) Suggested HPO
Bilateral sensorineural hearing loss Clinical sign Congenital–infancy (often diagnosed ~2–8 months) Near-universal (reported in essentially all cases) HP:0000407 (Sensorineural hearing impairment)
Generalized dystonia Motor symptom Childhood–adolescence–young adulthood (range ~12–34 y at onset) Universal (defining feature); progressive, often severe/disabling HP:0007325 (Generalized dystonia) / HP:0012622 (Chronic progressive)
Craniofacial dysmorphism (mild) Physical sign Congenital Frequent but variable severity — some cases (e.g., Argentinean family, Hutterite case) lack dysmorphism entirely HP:0000271 (Abnormality of the face)
Midline structural brain malformation (corpus callosum/vermis hypoplasia) Physical/imaging sign Congenital Variable — present in original twin cases and some later reports, absent in others (e.g., PMC5405358 case had no midline malformation) HP:0002079 (Hypoplasia of the corpus callosum), HP:0001320 (Cerebellar vermis hypoplasia)
Developmental delay / mild intellectual disability Neurodevelopmental Infancy–childhood Common but not universal; at least one adult-onset case (Argentinean proband) had no cognitive impairment HP:0001263 (Global developmental delay), HP:0001249 (Intellectual disability)
Hypotonia, poor suck, feeding/swallowing difficulty Neonatal sign Neonatal Reported in multiple cases HP:0001252 (Hypotonia), HP:0002015 (Dysphagia)
Dystonic tremor / jerky action tremor Motor symptom Adolescence Reported HP:0025230 (Dystonic tremor)
Bulbar dystonia (dysphagia, velopharyngeal insufficiency) Motor symptom, complication Adolescence (progressive) Reported in severe/fatal case HP:0002310 (Dysarthria)/HP:0002015
Parkinsonism (bradykinesia, resting/action tremor) Motor symptom Later adult onset (~40s) Reported in at least one family member, "expanding the phenotype" HP:0001300 (Parkinsonism)
Vision problems (cataracts, other) Clinical sign Variable Reported per GARD summary HP:0000518 (Cataract)
Scoliosis/kyphosis Skeletal sign Childhood–adolescence Reported HP:0002650 (Scoliosis)
Short stature Growth Childhood Reported in a subset HP:0004322 (Short stature)

Severity and progression: Dystonia is typically progressive, evolving from focal onset (e.g., writer's cramp, lower-limb gait dystonia, unilateral upper-limb dystonia) to generalized, often axial and bulbar dystonia. In the most severe reported course, a patient became wheelchair- and then bed-bound within 3–5 years of motor onset and required emergency DBS for life-threatening status dystonicus-like decompensation (PMID:29788902); a Hutterite adolescent died at age 15 from complications of uncontrolled dystonia following status dystonicus (PMID:28487785). Conversely, milder, adult-onset, non-progressive-to-cognition-sparing courses are also documented (Argentinean family, PMID:35005077), indicating wide phenotypic variability even with the identical p.Arg183Trp allele.

Quality of life impact: Severe cases show major functional impact — loss of ambulation, need for wheelchair/bed confinement, cochlear implantation for communication, feeding-tube dependency in bulbar involvement, and profound disability requiring full-time caregiver support; DBS responders regain sitting, standing-with-support, and ambulation with assistance (PMID:29788902).

Sources: PMID:16685646; PMID:29788902; PMID:28487785; PMID:35005077; PMID:31970217; GARD

4. Genetic/Molecular Information

Causal gene: ACTB (HGNC:132; NCBI Gene 60; OMIM *102630), chr7p22.1, 6 exons, encoding a 374-amino-acid, ~41.7 kDa cytoplasmic β-actin protein — one of the most highly expressed and evolutionarily conserved structural proteins in the human proteome.

Pathogenic variant details: - Variant: NM_001101.5:c.547C>T; p.(Arg183Trp) — the dominant recurrent DDS1 allele - Classification (ACMG/ClinVar): Pathogenic/Likely pathogenic, recurrent de novo and dominantly inherited; ClinVar entry RCV000019937 - Variant type: Missense (single nucleotide substitution, Arg→Trp at codon 183) - Location: Arg183 sits within the ATP-binding cleft/nucleotide-binding pocket of the actin monomer, a highly conserved residue (conserved across ~100 vertebrate species per UCSC alignment) - Allele frequency: Absent from population databases — reported "not present in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project" (PMID:28487785); consistent with absence from gnomAD, as expected for a de novo dominant lethal-severity variant - Somatic vs. germline: Germline (constitutional); documented de novo occurrences confirmed by trio exome sequencing in multiple independent families, plus vertical transmission in at least two multigenerational pedigrees - Functional consequence: Dominant-negative/altered-function mechanism — the mutant monomer incorporates into filaments and alters F-actin polymerization/depolymerization dynamics rather than causing simple loss of function (see §6) - A second reported ACTB variant in this syndrome is c.1023C>T (p.Ile341=), a synonymous change of uncertain/contested significance, listed in ClinVar under this same disease term (RCV002253209)

Modifier genes: No formal modifier locus identified; ACTG1 (γ-actin) is proposed as an endogenous molecular compensator — differential β-actin/γ-actin ratios across tissues and developmental stages are hypothesized to explain the tissue- and age-specific pattern of disease expression (craniofacial → cochlear → striatal), and its variable upregulation may account for phenotypic severity differences between otherwise genetically identical carriers (PMID:29788902).

Epigenetic information: No disease-specific epigenetic (DNA methylation/histone) data have been reported for DDS1; not covered in ENCODE/Roadmap Epigenomics disease-specific studies to date.

Chromosomal abnormalities: DDS1 itself is a point-mutation disorder, not a copy-number disorder. However, 7p22.1 contiguous microdeletions encompassing ACTB cause a related but distinct phenotype (developmental delay, short stature, microcephaly) and should be distinguished on chromosomal microarray/CMA from the single-nucleotide DDS1 variant (GeneCards ACTB).

Allelic series — genotype-phenotype correlation: ACTB is now recognized as a multi-phenotype actinopathy gene: - p.Arg183Trp → DDS1 (deafness-dystonia-predominant, later-onset progressive movement disorder) - p.Arg196His (recurrent) and other hotspot variants → Baraitser-Winter syndrome type 1 (more severe cortical malformation, pachygyria, characteristic craniofacial gestalt) — mechanistically distinguished by variant-specific effects on Arp2/3-mediated branching and myosin interaction rather than on simple polymerization rate (PMC12443469; PMC3677859)

Ontology suggestions: gene — HGNC:132 (ACTB); variant functional impact — best modeled as functional_impact_category: OTHER/altered-dynamics rather than clean GAIN_OF_FUNCTION or LOSS_OF_FUNCTION, per the dismech guidance on qualitative pathway disruption.

Sources: OMIM *102630; PMID:16685646; PMID:28487785; ClinVar RCV000019937; GeneCards ACTB

5. Environmental Information

No environmental factors, lifestyle exposures, or infectious agents are implicated in DDS1 causation — it is a fully penetrant monogenic structural-protein disorder. No CTD, TOXNET, or epidemiological literature links environmental exposures to onset or severity. The only "environmental" modulators reported are iatrogenic/therapeutic (surgical DBS, pharmacologic dystonia management — see §12), not causal or risk-modifying exposures.

6. Mechanism / Pathophysiology

Ordered causal chain

  1. Germline heterozygous ACTB missense mutation (predominantly c.547C>T, p.Arg183Trp) alters the nucleotide (ATP)-binding pocket of the β-actin monomer → leads to abnormal actin monomer (G-actin) conformation and altered nucleotide-exchange kinetics (demonstrated in recombinant protein assays; PMID:16685646).
  2. The mutant monomer co-assembles into filaments (heterodimeric incorporation alongside wild-type β-actin and γ-actin) → results in filamentous actin (F-actin) with altered polymerization/depolymerization dynamics — reduced elongation rate and/or accelerated/aberrant depolymerization — rather than a simple structural absence of actin ("dominant-negative/altered-function" mechanism, not classic loss-of-function).
  3. Because β-actin performs distinct, tissue- and life-stage-specific roles, the same molecular lesion produces sequential, tissue-specific downstream consequences as different actin-dependent processes become rate-limiting at different developmental windows (proposed temporal-vulnerability model, PMID:29788902):
  4. a. Prenatal — neural crest cell migration. Actin-driven lamellipodial/filopodial motility is required for neural crest delamination and migration; disrupted dynamics → causes mild craniofacial dysmorphogenesis and, in more severe allelic variants (e.g., BWCFF-causing p.Arg196His), overt midline/cortical brain malformation via impaired neuronal migration (supported by loss-of-migration phenotypes in Actb-null neural crest cells in mouse, PLOS One 2014).
  5. b. Infancy — cochlear hair-cell stereocilia maintenance. β-actin (with γ-actin) is a principal structural component of the stereociliary F-actin core. Actin isoforms are largely dispensable for initial stereocilia development but become essential for stereocilia maintenance; mouse Actb-deletion models show progressive, high-frequency-first hearing loss with age due to structural stereocilia degeneration, not developmental failure (PMID:20976199; PLOS Genetics PMC2954897) → in humans, this leads to progressive/early sensorineural deafness as the altered-dynamics mutant actin destabilizes stereociliary actin turnover over time.
  6. c. Puberty–adulthood — striatal (and pallidal) synaptic/neuronal actin turnover. Actin cytoskeletal remodeling is essential for ongoing dendritic spine plasticity and synaptic maintenance in striatal medium spiny neurons. Chronic accumulation of dysfunctional actin turnover → results in progressive striatal neurodegeneration.
  7. Striatal/pallidal neurodegeneration is directly evidenced at autopsy in the original index twins: abundant eosinophilic spherical structures in the striatum, strongly immunoreactive for actin and actin-depolymerizing factor (ADF)/cofilin, "consistent with degenerating neurons and processes... suggesting a defect in actin turnover," with additional actin/ADF-cofilin immunoreactivity in the globus pallidus (PMID:29788902).
  8. This structural neurodegeneration → leads to measurable striatal dopaminergic/neuronal dysfunction: reduced DaT-SPECT striatal dopamine-transporter uptake, reduced D2-receptor binding on Epidepride-SPECT in the putamen (and to a lesser extent caudate), and reduced FDG-PET glucose uptake bilaterally in the striatum, particularly the putamen — the first in vivo neuroimaging confirmation, corroborating the twins' post-mortem findings (PMID:29788902).
  9. Loss of normal striatal/pallidal neuronal output → produces the clinical phenotype of progressive, severe, generalized dystonia (basal-ganglia circuit dysfunction), which in a subset of patients later evolves to include parkinsonism (bradykinesia, resting tremor) in the fifth decade, reflecting broader degeneration of dopaminergic circuitry over time.
  10. Partial phenotypic buffering: the authors propose that "partial compensation by the upregulation of other forms of actin, in particular gamma-actin, modulates the degree of severity and the temporal pattern of susceptibility" — explaining inter-individual variability in onset age, severity, and presence/absence of craniofacial or cognitive features despite an identical causal variant (inferred/hypothesis-level, not directly demonstrated in human striatal tissue).

Category detail

  • Molecular pathways: Actin cytoskeletal dynamics/turnover (polymerization–depolymerization cycle); ADF/cofilin-mediated filament severing and recycling; Arp2/3-complex-dependent branched-actin nucleation (implicated for the allelic BWCFF variants). GO: GO:0030036 (actin cytoskeleton organization); GO:0051015 (actin filament binding); GO:0007015 (actin filament organization).
  • Cellular processes: Cell migration (neural crest), stereocilia maintenance, synaptic/dendritic spine remodeling, and ultimately neurodegeneration (a form of accumulative proteinopathy-like process driven by cytoskeletal-protein dysfunction rather than classic protein aggregation).
  • Protein dysfunction: Altered-function (not simple loss-of-function) monomer incorporation causing filament instability — UniProt P60709 (human ACTB); structural work maps Arg183 to the ATP-binding cleft.
  • Tissue damage mechanism: Actin-turnover-defect-driven neuronal degeneration in striatum/globus pallidus, morphologically resembling axonal/dendritic spheroid (dystrophic neurite) formation.
  • Cell types involved: Cochlear outer/inner hair cells (CL:0000602/CL:0000601); striatal medium spiny neurons (CL:0000696); neural crest cells (CL:0000333); globus pallidus neurons.
  • Anatomical/GO suggestions for pathograph: GO:0030041 (actin filament polymerization), GO:0030042 (actin filament depolymerization), GO:0007605 (sensory perception of sound, downstream phenotype), GO:0050890 (cognition, for developmental delay branch).
  • Molecular profiling / advanced technologies: No transcriptomic, proteomic, or single-cell datasets specific to human DDS1 tissue have been published (autopsy immunohistochemistry is the only human tissue-level molecular data available); mouse Actb-null and hair-cell-specific conditional-knockout models provide the closest molecular-profiling proxies (PMID:20976199).

Sources: PMID:16685646; PMID:29788902; PMID:20976199 / PMC2954897; PMC12443469 (Baraitser-Winter mechanism, allelic comparator); PLOS One 2014, Actb neural crest

7. Anatomical Structures Affected

  • Organ level (primary): Inner ear (cochlea) — sensorineural hearing loss; central nervous system — basal ganglia (striatum, globus pallidus), and in some cases cerebral cortex/corpus callosum/cerebellar vermis (developmental malformation subset).
  • Organ level (secondary/complications): Musculoskeletal system (scoliosis/kyphosis secondary to dystonic posturing); GI/upper aerodigestive tract (dysphagia, aspiration risk from bulbar dystonia); ophthalmologic (cataracts reported in some cases); craniofacial skeleton (mild dysmorphism).
  • Body systems: Nervous system (primary), auditory system, musculoskeletal system, and craniofacial/developmental system.
  • Tissue/cell level: Cochlear hair-cell stereocilia (actin-rich structures); striatal medium spiny neurons and globus pallidus neurons (site of autopsy-confirmed degeneration); neural crest-derived craniofacial mesenchyme (developmental).
  • Subcellular level (GO Cellular Component): Cytoskeleton/actin cytoskeleton (GO:0015629); stereocilium actin core (GO:0032420); dendritic spine (GO:0043197).
  • UBERON suggestions: UBERON:0001851 (cortex of cerebral hemisphere — malformation subset), UBERON:0002435 (striatum), UBERON:0001875 (globus pallidus), UBERON:0001846 (cochlea/organ of Corti structures), UBERON:0009653 (stereocilium), UBERON:0002539 (corpus callosum).
  • Laterality: Bilateral and symmetric in essentially all reported features — bilateral sensorineural hearing loss, bilateral striatal/putaminal imaging abnormalities, generalized (non-lateralized) dystonia (though focal onset, e.g. unilateral writer's cramp, is reported before generalization).

Sources: PMID:29788902; PMID:31970217 (corpus callosum/vermis hypoplasia case)

8. Temporal Development

Onset: Multi-stage, sequential onset pattern rather than single-point onset: - Neonatal: hypotonia, weak suck, feeding difficulty (early, non-specific) - Infancy (typically diagnosed 2.5–8 months): bilateral sensorineural hearing loss - Childhood–adolescence (range documented: ~12–24 years, most commonly early-mid teens): focal-onset dystonia (commonly lower-limb gait disturbance or upper-limb/writer's cramp), progressing to generalized dystonia over months-to-years - Adulthood (documented as late as the 40s in one family member): late parkinsonism as an expanded phenotype

Onset pattern: Insidious/subacute for dystonia; the hearing loss is typically noted as congenital-to-early-infancy and is not itself progressive in most reports (though the underlying stereocilia-maintenance mechanism predicts a progressive component with age, as in the mouse model).

Progression: - Disease course is progressive and often severe for the dystonia component — from focal to segmental to generalized, with axial/bulbar involvement in severe cases, culminating in loss of ambulation, wheelchair/bed dependence, and in the most severe reported case, fatal status-dystonicus-like decompensation by age 15. - Progression rate is highly variable: some cases show relatively indolent, non-progressive adult-onset dystonia without cognitive decline (Argentinean proband); others show rapid, life-threatening decompensation within a few years of onset. - Disease duration: chronic, lifelong; no spontaneous remission reported. DBS can produce durable (years-long) symptomatic improvement but is not curative and outcomes can wane over time (one case showed sustained benefit from age 19 to 25, with subsequent decline attributed to disease progression/hardware factors) (ScienceDirect S1353802022003145). - Critical periods: the tissue-specific-vulnerability model implies three sequential critical windows — prenatal neural crest migration, infantile cochlear hair-cell maintenance, and peripubertal-to-adult striatal synaptic maintenance — each representing a period where actin-dependent processes become rate-limiting.

Sources: PMID:29788902; PMID:28487785; PMID:35005077

9. Inheritance and Population

Epidemiology: - Prevalence: Orphanet lists prevalence as <1 per 1,000,000 — among the rarest of Mendelian syndromes, with only a small number of published families/cases worldwide (roughly a dozen documented individuals across all reports as of 2025) (Orphanet 79107). - Incidence: Not formally estimated; too rare for population-based incidence studies.

Inheritance pattern: Autosomal dominant. Both de novo occurrence (multiple independently confirmed trios) and vertical transmission (parent-to-child, multi-generational Argentinean family) are documented.

Penetrance: High/complete for at least the deafness component in reported carriers; dystonia penetrance appears high but with substantial variability in age of onset and severity, and at least one carrier (a mother in the Argentinean family) manifested facial dystonia plus later parkinsonism rather than classic generalized dystonia — consistent with variable expressivity rather than reduced penetrance per se.

Expressivity: Markedly variable — presence/absence of craniofacial dysmorphism, presence/absence of structural brain malformation, presence/absence of cognitive impairment, and severity/tempo of dystonia all vary substantially among carriers of the identical p.Arg183Trp variant.

Genetic anticipation: Not reported/established (no repeat-expansion mechanism; not expected mechanistically for a fixed missense variant).

Germline mosaicism: Not specifically documented in the literature reviewed, though possible given de novo occurrence pattern typical of such variants; not formally studied.

Founder effects: No population-specific founder variant identified; the recurrent p.Arg183Trp allele has arisen independently (recurrent de novo mutation at a mutational hotspot codon) across genetically distinct families (European, North American Hutterite, South American/Argentinean), rather than reflecting a single ancestral founder haplotype.

Consanguinity: Reported in at least one case (Hutterite family, a genetically isolated founder population, though the variant itself arose de novo rather than through recessive consanguineous transmission) (PMID:28487785).

Carrier frequency: Not applicable/not estimable — autosomal dominant with de novo predominance, no population carrier-frequency data (variant essentially absent from gnomAD/ESP population databases).

Population demographics: - Affected populations reported: European-ancestry families (original twins), a Hutterite (North American founder-population) family, and a South American (Argentinean) family — suggesting no strong ethnic restriction, consistent with a recurrent de novo mutational mechanism at a hotspot rather than a single ancestral allele. - Sex ratio: no clear sex predilection reported (autosomal dominant; cases include both male and female probands). - Age distribution: hearing loss universally identified in infancy; dystonia onset spans adolescence to middle adulthood across the reported cohort.

Sources: Orphanet 79107; PMID:28487785; PMID:35005077

10. Diagnostics

Clinical tests: - Laboratory tests: No disease-specific biochemical/enzymatic biomarker exists (this is a structural-protein disorder, not a metabolic one — distinguishing it from the biochemically-positive SERAC1/MEGDEL deafness-dystonia phenocopy, which shows elevated urinary 3-methylglutaconic acid). - Imaging: - Brain MRI: variable — may show corpus callosum/cerebellar vermis hypoplasia in a subset, or be entirely unremarkable in others (e.g., normal MRI in the Argentinean proband); T2/FLAIR hyperintensity in caudate/basal ganglia reported in at least one case (PMID:28487785). - DaT-SPECT (dopamine transporter imaging): reduced striatal (putaminal) uptake - Epidepride-SPECT (D2-receptor imaging): reduced D2-receptor binding bilaterally in putamen, lesser degree in caudate - FDG-PET: reduced glucose metabolism bilaterally in striatum, particularly putamen — these three modalities together constitute the first in vivo demonstration of striatal dopaminergic/neuronal dysfunction and support DBS-candidacy assessment (PMID:29788902) - Audiometry: confirms bilateral sensorineural hearing loss, typically severe-to-profound, often prompting cochlear implantation - Electrophysiology: not centrally diagnostic, though standard EMG/dystonia work-up (to exclude peripheral causes) is typical in movement-disorder evaluation - Biopsy/pathology: not part of antemortem diagnostic work-up; the only histopathologic data are post-mortem autopsy findings (striatal eosinophilic spheroids, actin/ADF-cofilin immunoreactivity)

Genetic testing: - Recommended approach: ACTB gene sequencing should be included in the diagnostic work-up of any patient presenting with the combination of childhood/early-onset sensorineural deafness and delayed-onset generalized dystonia ("ACTB sequencing should be included in the work-up of dystonia-deafness syndrome," PMID:29788902). - Whole-exome sequencing (WES) has been the diagnostic modality in essentially every reported case, typically performed as trio-WES to establish de novo status, given the absence of a distinctive enough phenotype to prompt single-gene testing a priori. - Whole-genome sequencing (WGS): not specifically reported as used but would be expected to have equivalent yield for this coding missense variant. - Single-gene ACTB Sanger sequencing: used for cascade/confirmatory testing in familial cases (e.g., the Argentinean family) once the index variant was identified. - Chromosomal microarray/karyotype: relevant to exclude the phenotypically distinct 7p22.1 microdeletion syndrome, not for DDS1 itself, which is a point mutation. - Movement-disorder/dystonia gene panels: ACTB may or may not be included on standard early-onset dystonia panels; given its rarity, it is often identified only via broader exome analysis after panel-negative results.

Clinical/differential diagnosis: Key mimics/differentials in the "deafness + dystonia" phenotype family requiring molecular distinction: - Mohr-Tranebjaerg syndrome (TIMM8A/DDP1, X-linked, OMIM #304700) — deafness-dystonia-optic neuronopathy, X-linked recessive, includes visual failure and later cognitive decline - BCAP31-related "deafness, dystonia, and cerebral hypomyelination" (DDCH) (OMIM #300475, X-linked) - MEGDEL/SERAC1-related disease (OMIM #614739, autosomal recessive, mitochondrial — distinguishable by elevated urinary 3-methylglutaconic acid and Leigh-like MRI findings) - Baraitser-Winter cerebrofrontofacial syndrome (allelic, other ACTB or ACTG1 variants, more prominent pachygyria/craniofacial gestalt)

Screening: No population or newborn screening program exists for this ultra-rare disorder; case-finding is via clinical recognition of the deafness+dystonia combination followed by exome sequencing.

Sources: PMID:29788902; PMID:28487785; GeneReviews SERAC1 (comparator)

11. Outcome/Prognosis

  • Survival/mortality: No formal survival statistics exist given the tiny reported cohort; however, mortality has been directly documented — the original index twins both died in their early twenties from aspiration pneumonia secondary to severe adolescent-onset generalized dystonia, and a separately reported Hutterite adolescent died at age 15 from complications of uncontrolled dystonia (status dystonicus) (PMID:29788902; PMID:28487785). This indicates a potentially life-limiting prognosis in severe/untreated cases, primarily via bulbar dystonia complications (aspiration, dysphagia) rather than the underlying neurodegeneration itself.
  • Morbidity/function: Severe, often profound motor disability in advanced disease — loss of ambulation, wheelchair/bed dependence, need for assistance with all activities of daily living. Communication is further impaired by the combination of deafness and (in severe cases) bulbar dysarthria/dysphagia.
  • Quality of life: No formal EQ-5D/SF-36 data published for this ultra-rare condition; qualitative reports (e.g., "she could sit relaxed in a chair," "could walk with support" after DBS) serve as the closest functional outcome proxies.
  • Complications: Aspiration pneumonia (major cause of death in severe cases), status-dystonicus-like decompensation, contractures/skeletal deformity (scoliosis/kyphosis) from chronic dystonic posturing, DBS hardware-related complications in treated patients.
  • Recovery potential: With DBS treatment, substantial and durable (multi-year) functional recovery is achievable in appropriately selected cases (large reductions in Burke-Fahn-Marsden Dystonia Rating Scale scores sustained 2.5 months to several years post-implantation); without treatment, the natural history in severe cases trends toward progressive, disabling, and potentially fatal outcomes.
  • Prognostic factors: presence/severity of bulbar involvement (predicts aspiration risk); early recognition and DBS candidacy; possibly genotype (p.Arg183Trp specifically proposed as a marker identifying a "DBS-responsive" DDS subtype, PMID:36339314); degree of striatal dopaminergic dysfunction on functional imaging.
  • Prognostic biomarkers: DaT-SPECT/Epidepride-SPECT/FDG-PET striatal dysfunction severity has been proposed (not formally validated) as a potential biomarker correlating with dystonia severity and possibly DBS responsiveness.

Sources: PMID:29788902; PMID:28487785; ScienceDirect S1353802022003145; PMID:36339314

12. Treatment

There is no disease-modifying or gene-targeted therapy; all management is symptomatic, centered on the dystonia and the hearing loss.

Pharmacotherapy: - First-line medical dystonia management (oral agents such as trihexyphenidyl, baclofen; anticholinergics/muscle relaxants) is the conventional first step per general dystonia-treatment paradigms, but the literature specifically notes response is insufficient in many patients with this syndrome, necessitating escalation. - Botulinum toxin injection has been used, in at least one case providing initial symptom relief before progressive dystonia necessitated further/adjunctive therapy (NCIT:C1364 — Botulinum Toxin). - No specific pharmacogenomic (PharmGKB/CPIC) guidance exists for this ultra-rare condition. - No DOPA-responsiveness reported — in the fatal Hutterite case, dystonia was explicitly characterized as "DOPA-unresponsive, medically refractory" (PMID:28487785).

Surgical/interventional — the defining treatment modality for this syndrome: - Bilateral Deep Brain Stimulation of the internal globus pallidus (GPi-DBS) is the treatment most strongly and repeatedly documented as effective, across multiple independent case reports (PMID:29788902; PMID:36339314; ScienceDirect S1353802022003145; ScienceDirect S2590112525001100).

"Deep brain stimulation of the internal pallidum bilaterally should be strongly considered to treat generalized dystonia in ACTB p.Arg183Trp carriers." (PMID:29788902) - Documented outcome in the index case: Burke-Fahn-Marsden Dystonia Rating Scale (motor/disability) improved from 87/25 preoperatively to 21/13 at 2.5 months post-op, sustained at 26/14 (3 years) and 30/14 (4 years) post-op. - A separate report specifically frames p.Arg183Trp as potentially identifying a DBS-responsive DDS subtype, and a later "revisited" report describes long-term (multi-year) follow-up with continued — though not unlimited — benefit, tempered by disease progression and hardware-related factors over time. - Subthalamic nucleus (STN) DBS has also been reported as an alternative target with reported response in at least one case (PMID:36339314 title: "Dystonia-Deafness Syndrome: A Rare Deep Brain Stimulation Responsive Dystonia"). - NCIT suggestion: NCIT:C116237 or the general Surgical/Therapeutic Procedure branch for "Deep Brain Stimulation"; NCIT:C15329 (Surgical Procedure) as the parent action term with qualifiers/device annotation for the DBS device per the dismech device-vs-action convention.

Auditory/rehabilitative: - Cochlear implantation is standard management for the profound sensorineural hearing loss and is documented in multiple cases as enabling functional communication. - Physical therapy, occupational therapy, and speech/swallowing therapy are used adjunctively for motor and bulbar symptom management (NCIT:C15302 Physical Therapy; NCIT:C159273 Speech Therapy).

Experimental/investigational: No registered clinical trials specific to ACTB-DDS1 were identified (consistent with its ultra-rare status); no gene therapy, ASO, or targeted molecular therapy has been reported or is in development for this actinopathy.

Treatment outcomes / adverse events: GPi-DBS is generally well tolerated with hardware-related complications as the main procedural risk category; no syndrome-specific adverse-event database exists (too rare for FAERS-level signal detection).

Treatment strategy: Given medication-refractory dystonia is common, the literature converges on an algorithm of: (1) trial of oral antidystonic agents ± botulinum toxin, (2) early consideration of GPi (or STN) DBS once medical therapy fails or dystonia becomes severe/generalized/life-threatening, particularly once the p.Arg183Trp genotype is confirmed, given its specific association with good DBS responsiveness; (3) cochlear implantation for hearing rehabilitation, pursued independently and typically earlier in the disease course.

Sources: PMID:29788902; PMID:28487785; PMID:36339314; ScienceDirect S1353802022003145; ScienceDirect S2590112525001100

13. Prevention

  • Primary prevention: None available — this is a de novo/dominantly inherited structural-protein disorder with no modifiable risk factor; primary prevention is not applicable in the population-health sense.
  • Secondary prevention (early detection): Early genetic diagnosis (via exome sequencing) in a patient presenting with congenital/infantile sensorineural deafness allows anticipatory monitoring for dystonia onset, and early referral to a movement-disorder/DBS center once dystonia emerges, given the DBS-responsiveness data.
  • Tertiary prevention: Aggressive, early dystonia management (medical, then surgical) aims to prevent the most severe downstream complications — bulbar dysfunction, aspiration pneumonia, and loss of ambulation — which are the main drivers of morbidity/mortality in this condition.
  • Genetic counseling: Central to family management given autosomal dominant inheritance with both de novo and inherited transmission patterns documented; at-risk relatives of a confirmed carrier can be offered targeted single-gene (Sanger) testing, as illustrated in the multi-generational Argentinean family, to identify pre-symptomatic carriers for early audiologic and neurologic surveillance. Prenatal/preimplantation genetic testing is theoretically available for known familial variants but not specifically reported in the literature reviewed.
  • Screening: No newborn or population screening program exists; case detection relies on clinical phenotype recognition (audiology + movement-disorder evaluation) triggering genetic testing.
  • Public health/environmental/prophylaxis: Not applicable — no environmental or infectious component to intervene upon.

14. Other Species / Natural Disease

  • Taxonomy: Human disease phenotype has no confirmed naturally-occurring veterinary counterpart reported in OMIA or the veterinary literature reviewed. ACTB itself is essentially universally conserved across vertebrates (NCBITaxon:9606 Homo sapiens for the human disease; mouse ortholog Actb, MGI:87904, NCBI Gene 11461).
  • Orthologous gene: Mouse Actb (chromosome 5), highly conserved; used extensively as the prototypical "housekeeping" cytoskeletal gene, which is itself informative — the fact that a missense change in such a universally essential, highly constrained protein produces a viable, tissue-restricted human phenotype (rather than being embryonic lethal, as complete knockout is) underscores that DDS1 arises from an altered-function/dominant-negative mechanism, not haploinsufficiency.
  • Natural disease in animals: Not identified/reported; this appears to be a human-specific reported clinical entity (or at minimum, not yet described in veterinary case literature).
  • Comparative biology: Cross-species conservation of β-actin's role in neural crest migration, hair-cell stereocilia maintenance, and neuronal cytoskeletal dynamics (demonstrated in mouse models, see §15) supports mechanistic homology, even without a documented spontaneous animal phenocopy.
  • Zoonotic potential/transmission: Not applicable — genetic, non-infectious disorder.

15. Model Organisms

No mouse model carrying the specific human p.Arg183Trp DDS1 variant has been reported in the literature surveyed; available models instead establish the tissue-specific necessity of β-actin, supporting (but not directly replicating) the human disease mechanism:

  • Global Actb knockout (mouse): Homozygous Actb⁻/⁻ mice are embryonic lethal, despite compensatory upregulation of other actin isoforms — establishing that β-actin has essential, non-fully-redundant functions even amid isoform compensation (PLOS One 2014, neural crest).
  • Neural-crest-specific Actb loss (mouse): β-actin-null neural crest cells retain neural crest marker expression but show reduced delamination and migration arrest shortly after onset, associated with elevated apoptosis (not altered proliferation) — directly modeling the proposed prenatal craniofacial-dysmorphogenesis mechanism (PLOS One 2014, PMID referenced in search: also see PMC3677859 for actin gene review).
  • Hair-cell-specific Actb/Actg1 conditional knockout (mouse): β-actin and γ-actin are each individually dispensable for initial auditory hair-cell development and normal hearing in young mice, but are required for stereocilia maintenance — mice lacking β-actin in hair cells develop progressive, high-frequency-first hearing loss with age, with stereocilia pathology progressing from basal/high-frequency to middle cochlear-turn regions over time, closely paralleling (and mechanistically explaining) the human infantile-onset, potentially progressive sensorineural deafness phenotype (PMID:20976199; PMC2954897).
  • Model limitations: No existing animal model recapitulates the striatal/pallidal neurodegeneration and dystonia component of the human phenotype, nor carries the specific dominant p.Arg183Trp allele — this represents a significant gap; a knock-in mouse expressing the human R183W variant (rather than complete knockout) would be needed to model the "altered-dynamics" dominant mechanism and the striatal neurodegenerative phenotype seen at human autopsy.
  • Cellular models: Patient-derived fibroblasts and recombinant R183W β-actin protein have been used in vitro to demonstrate altered polymerization/depolymerization kinetics directly (PMID:16685646) — this remains the most direct functional-genomics evidence for the molecular mechanism.

Sources: PLOS One 2014 (Actb neural crest); PMID:20976199; PMC2954897; PMID:16685646; MGI:87904

Summary Table: Key Ontology Term Suggestions for KB Curation

Category Suggested term
Disease MONDO:0011823; OMIM:607371; ORPHA:79107
Causal gene hgnc:132 (ACTB)
Variant ACTB c.547C>T p.(Arg183Trp); ClinVar RCV000019937
Phenotype — hearing HP:0000407 (Sensorineural hearing impairment)
Phenotype — dystonia HP:0007325 (Generalized dystonia)
Phenotype — corpus callosum HP:0002079 (Hypoplasia of the corpus callosum)
Phenotype — cerebellar vermis HP:0001320 (Cerebellar vermis hypoplasia)
Phenotype — dev. delay HP:0001263 (Global developmental delay)
Phenotype — parkinsonism HP:0001300 (Parkinsonism)
Cell types CL:0000602 (auditory hair cell), CL:0000696 (medium spiny neuron), CL:0000333 (neural crest cell)
Biological process (GO) GO:0030036 (actin cytoskeleton organization), GO:0030041 (actin filament polymerization)
Anatomy (UBERON) UBERON:0002435 (striatum), UBERON:0001875 (globus pallidus), UBERON:0009653 (stereocilium)
Treatment (NCIT) NCIT:C15329 (Surgical Procedure, for DBS) + device qualifier; NCIT:C1364 (Botulinum Toxin)

Key limitations of the current evidence base

This is one of the rarest disorders in the medical literature — evidence derives entirely from ~10–15 individual case reports/small series spanning 2006–2025, no registry, no natural-history study, no clinical trial, and no animal model of the exact causal variant. Phenotypic variability is substantial even among carriers of the identical recurrent p.Arg183Trp allele, and prognostic/treatment conclusions (especially DBS responsiveness) are based on small numbers and should be curated with that caveat explicitly noted in evidence directness/evidence_source annotations.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 5
Quoted claims found in source 1
Quoted claims not found in source 4
References weighed for topical relevance 13
On topic 5
Off topic 0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

  • PMID:28487785: "not present in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project"
  • closest text in source: "This variant has not been observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project (ESP) or in over 60,000 individuals in the Exome Aggregation Consortium (ExAC) or in the whole genome sequences of 98 Hutterites [8]"
  • PMC:PMC5405358: "not present in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project"
  • closest text in source: "This variant has not been observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project (ESP) or in over 60,000 individuals in the Exome Aggregation Consortium (ExAC) or in the whole genome sequences of 98 Hutterites [8]"
  • PMID:28487785: "DOPA-unresponsive, medically refractory"
  • Text part not found as substring: 'DOPA-unresponsive, medically refractory'
  • PMC:PMC5405358: "DOPA-unresponsive, medically refractory"
  • Text part not found as substring: 'DOPA-unresponsive, medically refractory'

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 47
Resolved 43
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 4
Terms whose name was checked 12
Terms named correctly 10
Terms named as a different term 2

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0025230 (1 mention) - the report calls it "Dystonic tremor"; HP calls it Tendonitis
  • NCIT:C1364 (2 mentions) - the report calls it "Botulinum Toxin"; NCIT calls it Didemnin B

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI, OMIM.